background
earli
administr
appropri
antimicrobi
correl
better
prognosi
bacterem
patient
research
highlight
comparison
advers
impact
inappropri
empir
antibiot
therapi
patient
gramposit
gramneg
bacteremia
insuffici
method
retrospect
cohort
studi
adult
communityonset
monomicrobi
bacteremia
period
enrol
clinic
inform
retriev
medic
record
use
predetermin
case
record
form
antimicrobi
suscept
determin
disk
diffus
method
base
perform
standard
clinic
laboratori
standard
institut
propensityscorematch
analysi
perform
control
baselin
characterist
bacteremia
onset
gramposit
gramneg
group
propens
score
calcul
independ
predictor
crude
mortal
recogn
multivari
logist
regress
model
result
total
adult
gramposit
patient
gramneg
present
communityonset
monomicrobi
bacteremia
sixyear
period
recruit
bacteremia
sever
pitt
bacteremia
score
onset
initi
manifest
differ
two
group
basi
seven
independ
predictor
mortal
recogn
multivari
patient
gramneg
group
match
patient
gramposit
group
closest
propens
score
appropri
propensityscor
match
signific
differ
observ
baselin
characterist
patient
outcom
two
group
term
age
bacteremia
sever
major
comorbid
comorbid
sever
mortal
suscept
test
salmonella
speci
escherichia
coli
vitek
ii
result
isol
isol
rate
among
isol
bacteria
staphylococcu
aureu
frequent
identifi
pathogen
follow
pathogen
escherichia
coli
salmonella
speci
bacillu
cereu
clostridium
perfringen
campylobact
speci
yersinia
enterocolitica
pathogen
e
coli
salmonella
speci
campylobact
speci
show
similar
season
show
surg
infect
rate
summer
month
aureu
c
perfringen
b
cereu
season
differ
preval
c
perfringen
high
particularli
antibiot
suscept
pattern
isol
pathogen
e
coli
salmonella
speci
show
rel
high
resist
ampicillin
respect
tetracyclin
respect
salmonella
speci
show
resist
imipenem
conclus
studi
base
use
systemat
surveil
diarrheal
patient
provid
geograph
trend
bacteri
pathogen
antimicrobi
suscept
keyword
bacteri
diarrhea
antimicrobi
resist
salmonella
e
coli
gwangju
citi
compar
genom
analysi
global
clone
acinetobact
baumannii
clinic
isol
bloodstream
infect
l
guo
w
yu
b
zheng
xiao
background
acinetobact
baumannii
gain
signific
attent
emerg
multidrugresist
strain
associ
outbreak
hospit
infect
report
major
isol
belong
two
major
global
clone
especi
asia
almost
research
focus
antibiot
resist
epidemiolog
domain
clone
littl
known
strategi
bacterium
use
pathogenesi
use
compar
genom
method
compar
genom
differ
blood
sputum
baumannii
isol
belong
method
wg
perform
baumannii
isol
individu
chines
hospit
one
spit
sampl
one
blood
sampl
patient
core
genom
snp
use
reconstruct
phylogeni
sequenc
isol
withinpati
snp
differ
everi
individu
bloodstream
sputum
isol
identifi
time
recogn
genet
locat
snp
common
featur
bloodstream
infect
isol
result
observ
individu
pairwis
snp
also
differ
st
type
bloodspit
isol
major
st
type
blood
isol
ratio
spit
isol
low
detect
candid
gene
capsular
polysaccharid
lipopolysaccharid
function
relat
gene
point
mutat
blood
isol
may
associ
bloodstream
infect
conclus
use
wg
observ
potenti
gene
critic
abil
pathogen
caus
bloodstream
infect
studi
lay
foundat
futur
research
baumannii
gene
target
develop
novel
therapeut
human
pathogen
acinetobact
baumannii
pray
plasmid
ageold
stealthi
vehicl
transmiss
aminoglycosid
resist
overlook
ss
lean
cc
yeo
saw
swee
hock
school
public
health
nation
univers
singapor
singapor
biomed
research
centr
faculti
medicin
univers
sultan
zainal
abidin
malaysia
aris
drug
resist
gramneg
pathogen
led
era
antibiot
resist
forc
clinician
face
greatest
threatth
end
antibiot
use
acinetobact
baumannii
nosocomi
pathogen
rapidli
acquir
resist
past
two
decad
advanc
genom
sequenc
technolog
provid
platform
search
panacea
result
plethora
baumannii
genom
sequenc
databas
one
interest
featur
baumannii
genom
presenc
small
plasmid
around
kb
less
encod
antibiot
resist
gene
plasmid
tend
overlook
genom
analys
baumannii
mainli
focus
larger
conjug
plasmid
chromosom
featur
aim
provid
detail
analysi
praytyp
small
plasmid
found
variou
acinetobact
genom
possibl
role
transmiss
drug
resist
first
isol
south
africa
baumannii
sun
pray
plasmid
confer
resist
aminoglycosid
via
aadb
gene
subsequ
variou
pray
deriv
rang
size
kb
found
strain
worldwid
also
harbour
aadb
gene
intriguingli
potenti
replic
initi
protein
encod
within
pray
deriv
suggest
replic
may
mirror
enterobacteri
plasmid
util
host
rna
polymeras
replic
initi
anoth
featur
group
plasmid
presenc
moba
mobc
gene
along
put
origin
transfer
orit
infer
potenti
transmiss
plasmid
discoveri
kb
plasmid
permafrost
lwoffii
isol
contain
oritmobcmoba
region
plu
aminoglycosideresist
gene
indic
oritmobcmoba
region
like
backbon
common
ancestor
group
plasmid
common
ancestor
would
acquir
variou
gene
spread
acinetobact
speci
throughout
evolutionari
histori
procalcitonin
rapid
test
adjunct
biomark
earli
detect
bacteri
sepsi
prognost
valu
era
increas
use
empir
antibiot
cultureneg
sepsi
posit
bacteriolog
cultur
nonspecif
infect
marker
remain
inadequ
earli
detect
bacteri
sepsi
studi
aim
determin
use
rapid
procalcitonin
pct
earli
detect
bacteri
sepsi
prognost
valu
patient
recruit
intens
care
unit
medic
ward
clinic
train
centr
june
decemb
immunoassay
use
principl
immunochromatographi
perform
day
admiss
eighti
microlit
whole
blood
run
parallel
neg
posit
control
pct
valu
obtain
within
minut
match
risk
categori
bacteri
sepsi
base
manufactur
recommend
includ
extrem
high
risk
high
risk
moder
low
risk
pct
valu
respect
patient
exclud
due
dengu
remain
clinic
diagnos
bacteri
infect
patient
n
extrem
high
risk
develop
sepsi
n
n
n
patient
high
moder
low
risk
toward
sepsi
n
death
mainli
due
septic
shock
highest
number
found
extrem
high
risk
categori
follow
moder
risk
increas
valu
pct
ngml
day
rapid
pct
demonstr
remark
find
assist
earli
detect
bacteri
infect
guid
clinician
commenc
empir
antibiot
therapi
base
day
pct
valu
also
aid
predict
prognost
relat
sever
infect
monitor
pct
valu
audit
impact
select
report
fluoroquinolon
suscept
prescrib
habit
tertiari
hospit
g
foo
sy
tan
zc
loh
wt
chung
kl
chew
n
bagdasarian
nation
univers
hospit
singapor
background
select
report
antimicrobi
suscept
one
strategi
commonli
use
among
antimicrobi
stewardship
program
fluoroquinolon
fq
suscept
report
suppress
institut
april
time
result
releas
follow
special
request
clinician
april
fq
suscept
releas
part
routin
suscept
report
object
studi
evalu
whether
unmask
fq
suscept
result
effect
use
fq
culturedirect
treatment
infect
method
conduct
retrospect
review
inpati
intraven
oral
fq
prescript
culturedirect
therapi
two
month
period
prior
unmask
fq
april
fq
prescript
defin
appropri
appropri
altern
carbapenem
appropri
oral
agent
prior
discharg
overal
fq
util
measur
six
month
chang
protocol
result
fq
prescript
per
month
culturedirect
treatment
chang
protocol
versu
fq
prescript
per
month
afterward
percentag
inappropri
fq
use
also
increas
versu
unmask
frequent
indic
culturedirect
fq
inappropri
use
treatment
urinari
tract
infect
lower
respiratori
tract
infect
time
period
mean
monthli
fluoroquinolon
util
remain
unchang
defin
daili
dose
per
patient
day
unmask
fq
suscept
conclus
select
report
use
intervent
limit
number
inappropri
fluoroquinolon
prescript
turn
influenc
gramneg
resist
mrsa
cdifficl
rate
hospit
strategi
decreas
antibiot
resist
hospit
particularli
intens
care
set
method
antibiogram
profil
clinic
patholog
depart
nation
cardiovascular
center
harapan
kita
jakarta
retrospect
analyz
antibiot
restrict
polici
due
meropenem
usag
start
novemb
novemb
meropenem
resist
restrict
compar
result
isol
bacteria
identifi
mainli
sputum
specimen
common
bacteria
acinetobact
baumanii
pseudomona
aeruginosa
klebsiella
pneumonia
serratia
marcescen
follow
year
common
bacteria
acinetobact
baumanii
klebsiella
pneumonia
serratia
marcescen
pseudomona
aeruginosa
antibiot
resist
rate
bacteria
meropenem
blood
cultur
sputum
cultur
antibiot
restrict
polici
appli
number
decreas
blood
cultur
sputum
cultur
follow
year
antibiot
restrict
polici
conclus
meropenem
resist
pediatr
cardiac
intens
care
unit
declin
antibiot
restrict
polici
keyword
antibiot
restrict
antibiot
resist
meropenem
pediatr
cardiac
intens
care
unit
introduc
first
tripl
dotelisa
diagnost
kit
neospora
caninum
ibr
bvdv
namavari
kamkarsalehi
neospora
caninum
infecti
bovin
rhinotrach
ibr
bovin
viral
diarrhea
bvd
import
agent
caus
abort
cattl
worldwid
infect
agent
caus
reproduct
disord
lead
econom
loss
dairi
beef
herd
serolog
test
includ
elisa
calcul
best
diagnost
way
neospora
caninum
ibr
bvd
aim
studi
develop
multiplex
dotelisa
kit
simultan
detect
three
abort
agent
neospora
caninum
ibr
bvd
blood
sampl
collect
cow
histori
abort
northern
far
provinc
sera
sampl
evalu
multiplex
dotelisa
compar
commerci
elisa
kit
result
show
rate
posit
sera
use
commerci
kit
neospora
caninum
ibr
bvdv
dotelisa
point
respect
kappa
agreement
assess
demonstr
appropri
agreement
multiplex
dotelisa
result
elisa
kit
mcnemar
test
show
method
efficaci
identif
abort
agent
result
studi
reveal
multipl
dotelisa
kit
could
simpl
econom
method
simultan
detect
three
abort
agent
cattl
experiment
kit
design
first
step
design
multipl
kit
diagnosi
infect
cow
could
introduc
complementari
studi
commerci
kit
futur
keyword
multiplex
dotelisa
elisa
neospora
caninum
ibr
bvd
evalu
role
microbiolog
molecular
biolog
test
earli
detect
pathogen
caus
lower
respiratori
infect
ph
van
vd
chien
tt
kieu
pt
huong
nguyen
tri
phuong
hospit
namkhoa
co
background
aim
base
pathogenesi
lower
respiratori
tract
infect
first
specimen
obtain
patient
detect
caus
microbi
agent
sputum
specimen
howev
sputum
contamin
specimen
big
challeng
must
overcom
confirm
isol
bacteria
pathogen
contamin
one
addit
common
pathogen
lower
respiratori
tract
infect
fastidi
bacteria
requir
immedi
isol
multipl
media
anoth
specimen
collect
detect
bacteri
pathogen
caus
pneumonia
blood
cultur
main
challeng
blood
cultur
ratio
blood
cultur
blood
cultur
diagnosi
pneumonia
often
low
sometim
fals
posit
contamin
blood
cultur
must
done
right
time
appropri
blood
cultur
media
serolog
immunochem
test
detect
specif
antibodi
antigen
caus
pathogen
main
solut
detect
pathogen
cultur
routin
clinic
laboratori
like
virus
atyp
bacteria
kind
test
often
sensit
specif
enough
antigen
igm
detect
well
clinic
relev
igg
detect
innov
feasibl
solut
present
abl
detect
microbi
agent
caus
lri
use
multiplex
realtim
pcr
techniqu
thank
high
sensit
specif
easili
perform
clinic
laboratori
due
moder
invest
cost
implement
autom
method
result
solut
evalu
sever
studi
conduct
nguyen
tri
phuong
children
hospit
real
project
receiv
result
shown
multiplex
realtim
pcr
capabl
detect
pathogen
microbi
agent
sensit
sever
time
higher
routin
method
model
implement
solut
call
streamlin
realtim
pcr
two
basic
devic
automat
dnarna
extract
machin
use
nk
dnarnaprepmagbead
realtim
pcr
machin
use
kit
includ
nk
aribac
realtim
pcr
detect
commun
bacteria
nk
ariatypicalbac
realtim
pcr
detect
atyp
bacteria
nk
ariviru
realtim
pcr
detect
viral
pathogen
nk
hapvapbac
realtim
pcr
detect
nosocomi
bacteria
caus
hap
vap
bacteri
pathogen
conclus
solut
result
detect
microbiolog
pathogen
caus
lower
respiratori
infect
arriv
physician
time
avoid
use
empir
antibiot
treatment
longtim
sinc
target
antibiot
treatment
done
patient
sort
time
clinic
diagnosi
keyword
microorgan
pathogen
caus
pneumonia
lower
respiratori
tract
infect
product
evalu
kit
use
magnet
silica
coat
nanoiron
bead
extract
nucleic
acid
differ
sampl
ph
van
bt
thanh
nv
quoc
nq
viet
pt
huong
nguyen
tri
phuong
hospit
nam
khoa
co
univers
medicin
pharmaci
pham
ngoc
thach
univers
medicin
introduct
pcr
techniqu
vietnam
appli
mani
diagnost
laboratori
howev
output
qualiti
vari
background
clinic
practic
often
difficult
distinguish
true
bacteremia
fals
bacteremia
studi
aim
evalu
time
posit
ttp
procalcitonin
pct
level
ttppct
ratio
reliabl
predictor
distinguish
true
bacteremia
contamin
blood
cultur
intravascular
cathet
colon
method
studi
retrospect
conduct
univers
hospit
south
korea
januari
decemb
subject
includ
febril
hospit
adult
patient
year
one
posit
blood
cultur
avail
ttp
pct
data
clinic
find
patient
meticul
review
infecti
diseas
physician
posit
blood
cultur
categor
true
bacteremia
inconclus
bacteremia
true
bacteremia
defin
two
clinic
relev
posit
blood
cultur
obtain
separ
occas
inconclus
bacteremia
defin
contamin
singl
posit
blood
cultur
cathet
colon
result
studi
period
patient
enrol
includ
true
bacteremia
inconclus
bacteremia
multivari
analysi
urinari
tract
infect
odd
ratio
confid
interv
ci
p
shorter
ttp
ci
p
independ
associ
true
bacteremia
true
bacteremia
case
ttp
significantli
shorter
gramneg
bacteremia
compar
gramposit
bacteremia
vs
p
base
primari
site
infect
ttp
significantli
shorter
urinari
tract
infect
nonurinari
tract
infect
vs
p
receiv
oper
characterist
curv
analysi
pct
level
cutoff
co
ngml
ttp
co
h
ttppct
ratio
co
h
mlng
show
sensit
specif
respect
conclus
studi
indic
shorter
ttp
presenc
urinari
tract
infect
may
reliabl
predictor
true
bacteremia
addit
ttppct
ratio
could
use
predict
true
bacteremia
keyword
procalcitonin
time
posit
ttppct
ratio
bacteremia
qnrb
gene
preval
citrobact
freundii
clinic
isol
howev
report
regard
coexist
qnrb
bla
gene
aim
studi
access
coexist
two
gene
potenti
multidrug
resist
transfer
character
mobil
element
involv
mic
antibiot
efflux
pump
inhibitor
determin
clinic
isol
transform
sitedirect
mutant
accord
guidelin
clsi
agar
dilut
method
molecular
character
gene
mobil
element
perform
pcr
amplif
dna
sequenc
pfge
southern
blot
analysi
coexist
encod
substitut
compar
bla
gene
detect
citrobact
clinic
isol
resist
fluoroquinolon
carbapenem
reduc
fluoroquinolon
suscept
attribut
substitut
gyra
substitut
parc
efflux
pump
qepa
oqxab
genet
context
surround
chromosom
novel
complex
class
integron
contain
uniqu
gene
array
bla
new
class
integron
nucleotid
delet
end
pspa
upstream
invert
repeat
region
detect
indic
past
transposit
event
fluoroquinolon
carbapenem
resist
associ
integron
could
relat
potenti
multidrug
resist
horizont
spread
worrisom
worldwid
stabil
trimethoprimsulfomethoxazol
resist
gene
strain
nontyp
haemophilu
influenza
z
mohdzain
sy
mohamad
nk
palanisami
n
ahmad
background
combin
trimethoprimsulfamethoxazol
sxt
commonli
use
treatment
haemophilu
influenza
infect
howev
nowaday
rare
use
treatment
due
emerg
h
influenza
sxtresist
strain
resist
trimethoprim
attribut
alter
structur
dihydrofol
reductas
gene
sulfonamid
resist
due
mutat
folp
gene
well
acquisit
gene
studi
investig
whether
resist
gene
strain
nontyp
h
influenza
nthi
could
transfer
h
influenza
type
b
hib
conjug
determin
integr
conjug
element
ice
involv
process
method
three
type
mate
procedur
filterpap
method
liquidsuspens
method
agarpl
method
carri
donor
recipi
ratio
volum
nthi
strain
resist
sxt
donor
hib
strain
resist
ampicillin
tetracyclin
chloramphenicol
recipi
follow
overnight
incub
transconjug
bear
resist
gene
enumer
pcr
use
detect
presenc
attb
strain
common
sequenc
attach
site
ice
result
repeat
trial
perform
fail
produc
transconjug
mate
method
attb
gene
detect
hib
strain
absent
nthi
strain
possibl
reason
conjug
transfer
sxtresist
gene
occur
conclus
gene
respons
sxt
resist
nthi
strain
stabl
chromosom
strain
lack
attb
ice
sitespecif
recombin
take
place
background
moraxella
catarrhali
one
import
pathogen
caus
infecti
diseas
signific
moraxella
catarrhali
communityacquir
pneumonia
increas
introduct
pneumococc
conjug
vaccin
haemophilu
influenza
type
b
vaccin
aim
studi
detect
antimicrobi
suscept
pattern
activ
characterist
moraxella
catarrhali
isol
collect
two
counti
hospit
china
method
antibiot
suscept
antimicrobi
test
use
etest
method
disc
diffus
test
result
interpret
refer
standard
european
committe
antimicrobi
suscept
test
eucast
clinic
laboratori
standard
institut
clsi
british
societi
antimicrobi
chemotherapi
bsac
detect
activ
determin
chromogen
cephalosporin
nitrocefin
oxoid
result
isol
suscept
amoxicillinclavulan
acid
suscept
rate
meropenem
accord
eucast
breakpoint
list
clsi
bsac
nonsuscept
rate
sulfamethoxazoletrimethoprim
two
counti
show
signific
differ
matter
judgment
criteria
use
isol
zhongjiang
sensit
strain
youyang
total
posit
rate
case
case
youyang
case
zhongjiang
conclus
almost
moraxella
catarrhali
isol
produc
isol
show
poor
suscept
ampicillin
erythromycin
high
suscept
rate
thirdand
fourthgener
cephalosporin
amoxicillinclavulan
signific
discrep
differ
antimicrobi
suscept
breakpoint
criteria
moraxella
catarrhali
moraxella
catarrhali
antibiot
resist
children
preval
antimicrobi
drug
resist
pattern
earli
urinari
tract
infect
among
renal
transplant
recipi
nepal
r
shrestha
tribhuvan
univers
nepal
background
urinari
tract
infect
uti
major
posttranspl
bacteri
infect
renal
transplant
recipi
major
infect
encount
first
three
month
transplant
first
studi
conduct
aim
determin
preval
drug
resist
pattern
earli
uti
among
renal
transplant
recipi
human
organ
transplant
center
hotc
nepal
method
prospect
descript
studi
conduct
among
renal
transplant
recipi
transplant
april
decemb
hotc
follow
month
transplant
patient
screen
uti
fortnightli
first
month
monthli
next
two
month
whenev
sign
symptom
suggest
uti
present
questionnair
fill
midstream
urin
catheter
urin
newli
insert
cathet
collect
process
accord
standard
methodolog
symptomat
asymptomat
case
bacteri
coloni
count
cfuml
includ
combin
disk
method
appli
detect
extend
spectrum
esbl
metallo
mbl
produc
isol
result
total
renal
transplant
recipi
includ
studi
n
male
n
femal
mean
age
gender
year
standard
deviat
year
total
episod
uti
observ
n
transplant
recipi
includ
male
femal
patient
vs
p
valu
gram
neg
bacteria
account
uti
episod
klebsiella
pneumonia
major
bacteria
isol
n
case
follow
e
coli
observ
n
case
isol
pseudomona
aeruginosa
enterococcu
spp
staphylococcu
aureu
citrobact
spp
gram
neg
isol
multidrug
resist
increas
level
resist
observ
drug
includ
pipracillin
ofloxacin
ceftazidim
cotrimoxazol
amoxycillin
alarmingli
high
resist
carbapenem
observ
among
isol
klebsiella
pneumonia
polymixin
b
colistin
sulphat
tigecyclin
drug
suscept
studi
show
high
preval
gram
neg
isol
produc
mbl
n
esbl
n
carbapenem
resist
due
carriag
mbl
alarmingli
high
among
isol
klebsiella
pneumonia
esbl
product
common
among
strain
e
coli
conclus
earli
uti
common
among
renal
transplant
recipi
complic
increas
preval
multidrug
resist
gram
neg
bacteria
harbor
esbl
mbl
proper
infect
control
guidelin
fit
context
better
adher
polici
studi
urgent
requir
better
manag
prevent
uti
drug
resist
bacteria
character
integron
antibiot
resist
e
coli
cattl
sheep
goat
iran
tahamtan
mostafae
microbiolog
depart
razi
vaccin
serum
research
institut
shiraz
branch
agricultur
research
educ
extens
organ
areeo
shiraz
iran
anim
scienc
faculti
agricultur
shahid
bahonar
univers
kerman
iran
background
e
coli
infect
major
health
problem
especi
among
anim
children
develop
countri
moreov
e
coli
becom
resist
commonli
use
antimicrobi
part
world
molecular
character
class
integron
preval
antibiot
resist
e
coli
cattl
sheep
goat
report
method
swab
stool
specimen
collect
cattl
sheep
goat
differ
part
far
provinc
iran
isol
character
perform
accord
standard
methodolog
includ
biochem
test
identif
e
coli
pcr
detect
integron
gene
isol
result
e
coli
strain
isol
resist
least
one
antibiot
resist
amoxicillin
penicillin
tetracyclin
ampicillin
cotrimoxazol
erythromycin
neomycin
gentamicin
amikacin
suscept
sulfamethoxazol
enorfloxacin
cefalexin
preval
integron
e
coli
isol
lack
antibiot
suscept
antibiot
associ
presenc
bacteria
discuss
e
coli
may
select
specif
gene
cassett
antibiot
select
pressur
result
class
integron
differ
horizont
transfer
conjug
plasmid
could
respons
dissemin
class
integron
keyword
class
integron
antibiot
resist
cattl
sheep
goat
e
coli
horizont
gene
transfer
antibiot
resist
gene
among
acinetobact
baumannii
u
leungtongkam
r
thummeepak
k
tasanapak
sitthisak
depart
microbiolog
parasitolog
faculti
medic
scienc
naresuan
univers
phitsanulok
thailand
conjug
horizont
gene
transfer
hgt
provid
import
mechan
acceler
spread
antibiot
resist
gene
gram
neg
bacteria
studi
aim
determin
gene
transfer
extens
drugresist
baumannii
xdrab
baumannii
isol
environ
use
conjug
antibiot
suscept
determin
carbapenemas
resist
gene
bla
bla
aminoglycosid
resist
gene
tetracyclin
resist
gene
tetb
detect
isol
drug
suscept
acinetobact
spp
recipi
select
sodium
azid
resist
induct
two
isol
resist
sodium
azid
use
recipi
conjug
assay
perform
investig
transfer
antibiot
resist
gene
strain
xdrab
two
sodium
azid
resist
isol
transconjug
recov
muellerhinton
agar
plate
contain
sodium
azid
plu
ticarcillin
plu
tetracyclin
plu
kanamycin
conjug
experi
demonstr
resist
ticarcillin
kanamycin
could
transfer
four
xdrab
donor
two
sodium
azid
resist
baumannii
conjug
frequenc
cf
ticarcillin
resist
vari
cf
kanamycin
resist
rang
transconjug
detect
lba
tetracyclin
found
donor
transfer
bla
gene
recipi
howev
bla
gene
neg
transconjug
donor
transfer
kanamycin
resist
gene
recipi
reppcr
profil
donor
recipi
transconjug
perform
band
pattern
transconjug
similar
recipi
work
underlin
effici
spread
antibiot
resist
gene
use
conjug
could
among
baumannii
fecal
carriag
carbapenem
resist
enterobacteriacea
among
inpati
univers
hospit
iran
object
fecal
colon
carbapenemresist
enterobacteriacea
cre
could
serv
reservoir
transmiss
pathogen
clinic
set
subsequ
increas
clinic
infect
aim
studi
evalu
preval
risk
factor
associ
cre
fecal
colon
among
inpati
materi
method
rectal
swab
patient
univers
hospit
collect
cre
screen
perform
use
select
media
carbapenemas
product
detect
phenotyp
test
pcr
assay
use
detect
carbapenemas
gene
clonal
related
investig
pulsedfield
gel
electrophoresi
pfge
result
preval
fecal
colon
overal
cre
isol
identifi
carbapenemaseproduc
eleven
patient
cocolon
cre
isol
icu
hospit
prior
antibiot
therapi
mechan
ventil
signific
risk
factor
bla
frequent
carbapenemas
follow
bla
andbla
enzym
nine
carpapenemas
produc
enterobacteriacea
cpe
isol
coharbor
bla
bla
also
six
cpe
isol
coharboredbla
bla
detect
bla
kpc
bla
ge
bla
imp
bla
vim
pfge
analysi
show
e
coli
clone
divers
k
pneumonia
categor
cluster
cluster
major
clone
carri
bla
bla
gene
conclus
studi
first
investig
iran
show
cre
high
preval
fecal
carriag
also
harbor
vari
antimicrobi
resist
element
background
republ
korea
carbapenemas
produc
enterobacteriacia
cpe
infect
patient
increas
everi
year
critic
problem
could
emerg
korean
public
health
system
june
june
two
hospit
republ
korea
suffer
outbreak
cpe
two
hospit
includ
nation
surveil
wherebi
korea
center
diseas
control
prevent
kcdc
complet
control
occur
patient
cpe
intervent
control
transmiss
herein
describ
medic
epidemiolog
characterist
cpe
patient
two
hospit
explain
control
nosocomi
transmiss
cpe
method
review
epidemiolog
investig
report
case
cpe
outbreak
hospit
hospit
patient
hospit
b
patient
also
review
medic
record
collect
data
clinic
cours
isol
cpe
analyz
nation
research
institut
health
korea
evalu
carbapenemas
base
microbiolog
result
confirm
outbreak
cpe
pulsedfield
gel
electrophoresi
pfge
perform
clarifi
epidemiolog
correl
result
hospit
total
patient
involv
cpe
klebsiella
pneumonia
kpc
type
carbapenemas
outbreak
occur
surgic
intens
care
unit
sicu
patient
transmit
sicu
patient
medic
intens
care
unit
micu
patient
expos
gener
ward
appli
intens
cpe
control
strategi
includ
activ
surveil
patient
isol
emphasi
contact
precaut
medic
staff
preemptiv
isol
month
later
cpe
outbreak
hospit
termin
hospit
b
patient
cpe
klebsiella
pneumonia
type
carbapenemas
outbreak
origin
neurosurg
intens
care
unit
nsicu
index
case
occur
sicu
admit
neurosurgeri
ns
depart
crossspread
doctor
ns
transmiss
cpe
nsicu
gener
close
nsicu
prevent
occurr
new
cpe
exposur
intervent
control
cpe
outbreak
outbreak
termin
within
month
conclus
experienc
cpe
outbreak
occur
base
hospit
set
success
control
situat
strictli
appli
strategi
infect
control
character
copper
resist
determin
among
acinetobact
baumannii
clinic
isol
r
thummeepak
thanwisai
n
chantratita
sitthisak
depart
microbiolog
parasitolog
faculti
medic
scienc
naresuan
univers
phitsanulok
thailand
depart
microbiolog
immunolog
faculti
tropic
medicin
mahidol
univers
bangkok
thailand
acinetobact
baumannii
gramneg
pathogen
bacterium
increas
preval
multipledrug
resist
strain
document
worldwid
copper
resist
one
import
mechan
requir
bacteri
surviv
environ
pathogenesi
work
aim
character
copper
suscept
preval
copper
associ
gene
express
profil
baumannii
clinic
isol
copper
associ
gene
detect
pcr
assay
clinic
isol
baumannii
obtain
hospit
thailand
copper
suscept
test
perform
agar
dilut
method
associ
gene
pattern
copper
resist
analyz
use
fisher
exact
test
repres
isol
select
studi
effect
copper
express
copperrel
gene
use
rtqpcr
preval
cuer
copr
gene
among
test
strain
respect
copper
suscept
studi
reveal
strain
high
mic
copper
mm
found
isol
isol
test
strain
mic
copper
lower
mm
found
cuer
copr
strain
resist
copper
mic
mm
cuer
copr
strain
copper
resist
strain
p
also
design
addit
primer
detect
structur
gene
cue
cop
operon
repres
strain
ab
found
ab
contain
two
structur
gene
gene
encod
copper
efflux
pump
multicopp
oxidas
cue
operon
cop
operon
contain
six
structur
gene
gene
encod
copb
copa
copc
copd
copper
efflux
pump
hypothet
protein
result
rtqpcr
show
gene
cue
operon
upregul
microand
millimolar
level
copper
gene
cop
operon
overexpress
millimolar
level
copper
suggest
cue
operon
intrins
resist
system
found
analyz
strain
cop
operon
associ
copper
resist
higher
concentr
copper
futur
studi
need
conduct
order
confirm
gene
function
involv
copper
resist
pathogenesi
keyword
acinetobact
baumannii
copper
suscept
copperassoci
gene
rtqpcr
concentr
gradient
carbapenem
exposur
alter
plasmid
copi
number
within
nosocomi
isol
escherichia
coli
harbor
bla
paul
dhar
bhattacharje
depart
microbiolog
assam
univers
silchar
medic
colleg
hospit
silchar
india
background
spread
bla
carbapenemas
underscor
potenti
threat
grave
concern
infect
manag
therapeut
option
howev
known
bacteria
harbor
resist
gene
respond
carbapenem
therapi
initi
patient
studi
investig
chang
plasmid
copi
number
bla
exposur
differ
concentr
carbapenem
method
clinic
isol
e
coli
harbor
bla
within
incfrepb
type
plasmid
grown
exposur
imipenem
meropenem
ertapenem
concentr
plasmid
extract
quantit
real
time
pcr
carri
estim
rel
copi
number
bla
fold
chang
normal
housekeep
gene
rpsel
stabil
bla
determin
serial
passag
without
antibiot
pressur
cure
plasmid
done
use
differ
concentr
sd
acridin
orang
ethidium
bromid
result
copi
number
bla
found
consist
higher
concentr
ertapenem
meropenem
increas
wherea
case
imipenem
vice
versa
plasmid
encod
bla
found
highli
stabl
could
success
elimin
singl
treatment
sd
consid
effici
cure
agent
cure
mutant
becam
suscept
carbapenem
quinolon
aminoglycosid
conclus
studi
could
establish
carbapenem
effect
interfer
plasmid
copi
number
conjug
transfer
propag
mainten
within
host
turn
help
bacteri
adapt
clinic
set
also
signific
futur
infecti
diseas
risk
assess
minim
select
pressur
within
hospit
environ
morbid
mortal
mechan
antibiot
resist
evolv
bacteria
mainli
includ
efflux
pump
activ
therefor
studi
aim
assess
efflux
pumpmedi
antibiot
resist
laboratoryinduc
clinic
isol
antibiot
resist
strain
salmonella
typhimurium
antibiot
suscept
typhimurium
atcc
wtst
ciprofloxacininduc
antibioticresist
typhimurium
atcc
cist
clinicallyacquir
antibioticresist
typhimurium
atcc
cast
determin
absenc
presenc
clavulan
sulbactam
tazobactam
efflux
pump
cccp
inhibitor
efflux
pump
activ
wtst
cist
cast
measur
nitrocefin
hydrolysi
ethidium
bromid
etbr
accumul
assay
respect
suscept
wtst
cist
cast
class
antibiot
fluoroquinolon
aminoglycosid
macrolid
consider
increas
presenc
efflux
pump
inhibitor
activ
respect
wtst
cist
cast
increas
expos
ceftriaxon
etbr
residu
remain
high
cist
cast
treat
studi
would
provid
use
inform
better
underst
develop
antibiot
resist
associ
efflux
pump
activ
design
new
antibiot
chemotherapi
combin
inhibitor
analysi
esblposit
isol
repres
conjug
subject
detail
character
wholegenom
sequenc
result
e
hormaechei
e
kobei
predomin
among
isol
mlst
distinguish
st
polyclon
structur
preval
clone
detect
north
china
interand
intraregion
clonal
dissemin
identifi
analysi
coregenom
snp
twentytwo
isol
esbl
posit
half
e
kobei
esbl
produc
n
exclus
classifi
e
hormaechei
e
kobei
bla
preval
genotyp
n
detect
within
four
genet
context
inchityp
plasmid
preval
esblposit
isol
especi
esbl
produc
plasmid
carri
esbl
gene
share
similar
backbon
plasmid
recov
salmonella
enterica
canada
conclus
e
kobei
e
hormaechei
predomin
reservoir
esbl
gene
plasmid
larg
contribut
dissemin
esbl
gene
commun
china
speci
distribut
speciesdepend
esbl
mechan
identifi
studi
suggest
necess
tailor
surveil
bacterium
futur
vitro
activ
tigecyclin
compar
multi
drug
resist
mdr
enterobacteriacea
africa
middl
east
afm
asiapacif
ap
conclus
k
pneumonia
common
pathogen
express
resist
broad
spectrum
antimicrobi
activ
drug
base
tigecyclin
amikacin
meropenem
higher
phenotypicposit
esbl
rate
observ
among
k
pneumonia
afm
compar
ap
region
propens
k
pneumonia
develop
resist
resist
continu
spread
continu
monitor
import
pathogen
global
region
surveil
warrant
isol
identifi
suscept
test
local
use
broth
microdilut
methodolog
accord
clsi
guidelin
clsi
breakpoint
criteria
appli
defin
suscept
rate
fda
breakpoint
use
tigecyclin
result
suscept
agent
organ
provid
follow
tabl
conclus
tigecyclin
meropenem
amikacin
agent
consist
provid
suscept
enter
speci
howev
given
propens
suscept
trend
among
organ
chang
time
continu
surveil
monitor
chang
among
key
gramneg
bacilli
countri
warrant
patient
kp
bsi
neutropenia
multipl
organ
dysfunct
respiratori
failur
cnskp
infect
high
apach
ii
score
tigecyclin
therapi
independ
associ
higher
mortal
risk
among
patient
whose
apach
ii
score
higher
mortal
rate
observ
patient
treat
tigecyclin
treat
antibiot
versu
p
conclus
signific
increas
incid
cnskp
bsi
observ
studi
period
higher
mortal
rate
seen
patient
exposur
carbapenem
sever
ill
independ
risk
factor
develop
cnskp
bsi
tigecyclin
therapi
result
signific
increas
mortal
complet
genom
sequenc
genom
character
two
clinic
escherichia
coli
strain
coproduc
x
method
isol
subject
edtaand
phenylboron
acid
pba
carbapenem
combin
disk
test
character
phenotyp
genotyp
method
result
isol
confirm
class
carbapenemas
produc
presenc
synergi
imipenem
pba
follow
pcr
nucleotid
sequenc
bla
chromosom
encod
gave
indistinguish
ericpcr
pattern
neither
extendedspectrum
esbl
plasmidmedi
quinolon
resist
pmqr
found
isol
lack
ompf
contain
ident
ompc
variant
isol
remain
suscept
third
gener
cephalosporin
resist
carbapenem
higher
level
resist
imipenem
mic
mgl
ertapenem
meropenem
addit
resist
colistin
mgl
patient
improv
antimicrobi
therapi
either
coamoxiclav
meropenem
conclus
report
enzym
may
due
poor
hydrolysi
activ
thirdgener
cephalosporin
suggest
awar
unusu
resist
profil
imi
produc
statist
signific
trend
time
found
countri
howev
thailand
vietnam
show
greater
rate
esbl
countri
analysi
suscept
pattern
across
countri
perform
use
data
last
year
combin
increas
sampl
size
suscept
southeast
asia
overal
low
cephalosporin
fluoroquinolon
suscept
especi
reduc
vietnam
respect
thailand
respect
correspond
high
esbl
rate
countri
studi
agent
amikacin
ertapenem
imipenem
demonstr
suscept
countri
conclus
esbl
e
coli
rate
high
southeast
asia
overal
rel
stabl
rate
vari
countri
especi
high
level
seen
vietnam
thailand
expect
consid
high
esbl
rate
coresist
often
found
esbl
isol
suscept
low
cephalosporin
fluoroquinolon
limit
therapeut
option
uti
southeast
asia
background
opportun
safe
success
treatment
carbapenemresist
acinetobact
bacteremia
crab
bacteremia
appropri
antibiot
aa
limit
real
world
howev
survivor
without
aa
exist
aim
review
clinic
featur
patient
order
character
potenti
favor
prognost
factor
surviv
without
aa
method
patient
age
year
crab
bacteremia
retrospect
identifi
apr
mar
five
hospit
locat
south
korea
use
aa
defin
administr
antimicrobi
agent
caus
pathogen
suscept
hour
within
day
onset
bacteremia
case
survivor
defin
patient
surviv
day
without
use
aa
control
death
defin
patient
die
within
day
blood
cultur
without
use
aa
antimicrobi
suscept
test
agar
dilut
method
accord
clsi
guidelin
follow
antimicrobi
test
piperacillin
piperacillintazobactam
cefoxitin
cefotetan
imipenem
meropenem
clindamycin
moxifloxacin
chloramphenicol
metronidazol
inoculum
cfu
appli
steer
replic
plate
incub
anaerob
chamber
h
b
fragili
atcc
b
thetaiotaomicron
atcc
use
control
result
isol
test
suscept
piperacillintazobactam
imipenem
meropenem
resist
rate
three
antimicrobi
lower
resist
rate
imipenem
piperacillintazobactam
respect
nonfragili
bacteroid
spp
organ
howev
much
higher
resist
rate
observ
piperacillin
cefotetan
clindamycin
b
fragili
group
nonfragili
bacteroid
spp
parabacteroid
spp
overal
prevotella
fusobacterium
isol
suscept
b
fragili
group
organ
anaerob
gnb
suscept
antibiot
test
conclus
piperacillintazobactam
cefoxitin
carbapenem
highli
activ
agent
gnb
continu
monitor
necessari
detect
antimicrobi
resist
pattern
chang
background
despit
discoveri
radiat
energi
hundr
year
ago
signific
research
perform
demonstr
effect
bacteria
revers
carbapenem
resist
mdr
klebsiella
pneumonia
use
radait
method
overnight
cultur
bacteria
treat
mev
proton
particl
energi
gy
dosag
replica
plate
perform
screen
suscept
mutant
omp
profil
determin
genom
dna
sequenc
use
ion
torrent
pgm
pacbiosmrt
sequenc
genom
snp
analysi
perform
use
geneiou
pro
result
among
coloni
screen
replica
plate
seven
carbapenem
suscept
k
pneumonia
mutant
obtain
mic
meropenem
ertapenem
chang
respect
wg
analysi
reveal
wildtyp
mutant
strain
found
bla
bla
temb
bla
betalactamas
gene
howev
excis
kb
nucleotid
fragment
plasmid
associ
class
integron
encod
bla
gene
one
suscept
mutant
interestingli
neither
invert
ir
direct
repeat
dr
detect
presum
due
two
transposas
gene
locat
end
leav
irdr
mark
addit
snp
two
novel
efflux
pump
mutant
found
absent
wild
type
mutant
conclus
loss
function
two
novel
efflux
pump
along
delet
kb
nucleotid
fragment
induc
so
respons
due
radiat
might
revers
carbapenem
resist
mediat
knockout
studi
progress
understand
conclus
role
target
aureu
visa
associ
treatment
failur
hvisa
could
detect
simpl
disc
diffus
method
current
specif
genet
marker
hvisa
detect
sever
genet
alter
report
associ
lowlevel
vancomycin
resist
aureu
aim
studi
compar
isaa
rpln
gene
express
visa
hvisa
vancomycinsuscept
aureu
vssa
isol
method
total
mrsa
isol
classifi
vssa
hvisa
visa
popul
analysi
profil
area
curv
papauc
express
level
isaa
rpln
gene
isol
determin
rel
quantif
real
time
rtpcr
use
rrna
refer
gene
minimum
inhibitori
concentr
vancomycin
determin
agar
dilut
method
result
rang
papauc
vssa
hvisa
visa
group
vancomycin
mic
respect
visa
isol
show
signific
higher
rel
express
isaa
hvisa
vssa
fold
respect
p
wherea
rpln
mean
rel
express
hvisa
fold
higher
vssa
p
conclus
preliminari
studi
reflect
potenti
role
isaa
rpln
express
tool
differenti
hvisa
visa
vssa
nocardia
speci
ubiquit
bacteria
caus
sever
dissemin
infect
human
antibiogram
larg
speciesspecif
suscept
test
routin
perform
nocardia
speci
sulphonamid
remain
cornerston
treatment
howev
increas
sulphonamid
resist
report
geograph
variabl
speci
distribut
resist
rate
need
understand
local
epidemiolog
detect
emerg
resist
institut
studi
aim
survey
distribut
antimicrobi
suscept
clinic
nocardia
speci
receiv
larg
tertiari
hospit
australia
antimicrobi
suscept
test
perform
clinic
nocardia
isol
receiv
januari
decemb
use
rapmycoi
microdilut
panel
trek
diagnost
system
ltd
thermo
scientif
identifi
partial
rrna
andor
sequenc
panel
antibiot
test
amikacin
amoxicillinclavunal
cefepim
cefoxitin
ceftriaxon
ciprofloxacin
moxifloxacin
clarithromycin
trimethoprimsulfamethoxazol
doxycyclin
minocyclin
imipenem
linezolid
tobramycin
tigecyclin
three
frequent
isol
nocardia
speci
nocardia
nova
complex
n
nocardia
cyriacigeorgica
complex
n
nocardia
brasiliensi
n
speci
isol
includ
nocardia
farcinica
n
nocardia
psuedobrasiliensi
n
nocardia
beijingensi
n
nocardia
abscessu
complex
n
nocardia
transvalensi
complex
n
nocardia
speci
n
test
strain
isol
display
resist
trimethoprimsulfamethoxazol
mic
resist
strain
n
farcinica
follow
n
pseudobrasiliensi
n
nova
complex
respect
half
isol
resist
imipenem
mic
isol
suscept
linezolid
amikacin
mic
valu
respect
major
resist
trimethoprimsulfamethoxazol
detect
nocardia
farcinica
linezolid
amikacin
remain
activ
agent
good
option
treatment
nocardia
infect
institut
induc
clindamycin
methicillin
resist
staphylococcu
aureu
tertiari
care
hospit
kathmandu
nepal
rp
adhikari
shrestha
barakoti
r
amatya
depart
microbiolog
nepal
medic
colleg
teach
hospit
jorpati
kathmandu
nepal
background
staphylococcu
aureu
frequent
caus
infect
continu
import
nosocomi
pathogen
infect
especi
methicillin
resist
one
often
difficult
manag
due
resist
multipl
antibiot
macrolidelincosamid
streptogramin
b
famili
antibiot
commonli
use
treat
infect
altern
vancomycin
method
descript
cross
section
studi
conduct
period
one
half
year
novemb
microbiolog
laboratori
nepal
medic
colleg
teach
hospit
kathmandu
nepal
find
incid
differ
phenotyp
ml
b
resist
among
aureu
clinic
sampl
associ
methicillin
resist
studi
done
nonrep
isol
aureu
clinic
specimen
pu
blood
urin
sputum
bodi
fluid
gender
age
group
patient
attend
nmcth
identif
aureu
first
done
use
coloni
morpholog
sheep
blood
agar
cream
golden
yellow
coloni
without
haemolysi
identifi
use
gram
stain
catalas
test
coagulas
test
standard
microbiolog
techniqu
antibiot
suscept
studi
modifi
kirbi
bauer
disc
diffus
method
mueller
hinton
agar
plate
cm
diamet
use
ampicillin
cotrimoxazol
ciprofloxacin
vancomycin
cephalexin
ug
gentamycin
ug
disc
cefoxitin
ug
detect
methicillin
resist
erythromycin
clindamycin
disc
himediaindia
mm
apart
also
use
plate
detect
induc
clindamycin
resist
per
clsi
guidelin
isol
cefoxitin
zone
size
mm
consid
methicillin
suscept
mm
consid
methicillin
resist
isol
resist
erythromycin
clindamycin
zone
mm
dshape
zone
regard
posit
induc
resist
ml
b
phenotyp
isol
resist
erythromycin
suscept
clindamycin
consid
neg
dtest
ms
phenotyp
resist
erythromycin
clindamycin
regard
constitut
resist
phenotyp
c
ml
b
isol
suscept
erythromycin
clindamycin
regard
suscept
strain
result
total
specimen
urin
blood
sputum
pu
bodi
fluid
process
inpati
outpati
isol
staphylococcu
aureu
male
patient
femal
patient
obtain
pu
blood
sputum
urin
bodi
fluid
respect
among
process
sampl
highest
posit
rate
found
pu
sampl
follow
sputum
blood
bodi
fluid
urin
among
antibiot
test
isol
suscept
vancomycin
gentamycin
still
found
better
action
compar
antibiot
howev
isol
resist
commonli
use
antibiot
higher
percentag
resist
erythromycin
clindamycin
among
mrsa
indic
wide
use
erythromycin
clindamycin
treatment
staphylococc
infect
set
resist
pattern
decreas
reduct
use
macrolid
studi
emphas
need
likewis
set
reserv
altern
drug
choic
treat
infect
caus
mrsa
low
level
suscept
erythromycin
resist
mrsa
toward
clindamycin
mean
least
chanc
clinic
efficaci
clindamycin
treat
erythromycin
resist
mrsa
infect
altern
vancomycin
find
emphas
need
dtest
perform
routin
set
avoid
clinic
failur
use
clindamycin
altern
antimrsa
antibiot
like
vancomycin
linezolid
keyword
staphylococcu
aureu
mrsa
induc
clindamycin
resist
nepal
introduct
major
communityassoci
mrsa
camrsa
strain
korea
spread
commun
healthcar
set
rais
seriou
public
health
concern
investig
potenti
genotypespecif
suscept
profil
host
defens
cation
antimicrobi
peptid
hdcap
assess
use
mrsa
strain
method
use
iv
ii
mrsa
clinic
isol
assess
antibiot
resist
profil
ii
suscept
hdcap
polymyxin
b
iii
rel
net
cell
surfac
charg
use
fitclabel
polyllysin
bind
assay
iv
transcript
profil
gene
involv
surfac
charg
regul
aureu
mprf
dltabcd
v
spa
type
superantigen
toxin
type
result
strain
exhibit
higher
level
antibiot
resist
especi
multidrug
resist
camrsa
strain
strain
also
display
higher
resist
pmb
kill
camrsa
strain
parallel
higher
level
surfac
posit
charg
link
enhanc
transcript
mprf
dltabcd
among
strain
conclus
camrsa
associ
lower
mortal
compar
mrsa
strain
suggest
camrsa
strain
less
virul
current
investig
data
suggest
lower
pathogen
mrsa
compar
mrsa
associ
higher
suscept
hdcap
one
critic
element
host
innat
immun
system
keyword
methicillinresist
staphylococcu
aureu
mrsa
host
defens
cation
antimicrobi
peptid
hdcap
genotyp
retrospect
analysi
staphylococcu
lugdunensi
suscept
p
rao
mendi
j
chia
tan
tock
seng
hospit
singapor
background
staphylococcu
lugdunensi
known
suscept
compar
coagulas
neg
staphylococci
penicillin
resist
rate
report
due
betalactamas
oxacillin
resist
rate
less
attempt
observ
tempor
suscept
trend
lugdunensi
method
retrospect
analysi
look
antibiot
suscept
data
lugdunensi
tertiari
care
centr
singapor
suscept
routin
perform
use
either
vitek
ii
kirbi
bauer
interpret
use
clsi
criteria
clsi
result
total
isol
lugdunensi
identifi
major
site
blood
urin
penicillin
resist
seen
isol
oxacillin
resist
isol
suscept
fluroquinolon
doxycyclin
trimethoprimsulfamethoxazol
resist
erythromycin
clindamycin
note
conclus
comparison
studi
conduct
singapor
show
penicillinresist
rate
seem
increas
penicillinresist
among
lugdunensi
isol
howev
oxacillin
antibiot
remain
larg
suscept
preliminari
studi
rna
polymeras
subunit
rpob
gene
mutationsin
vancomycinsuscept
nonsuscept
staphylococcu
aureu
isol
thai
univers
hospit
wongthong
p
tippayawat
chanawong
r
tavichakorntrakool
c
wilailuckana
lulitanond
visa
hvisa
isol
report
rpob
mutat
may
play
major
role
develop
vancomycin
resist
aureu
gene
encod
rna
polymeras
activ
catalysi
reaction
mutat
rpob
confer
transcript
activ
whole
rna
polymeras
common
mutat
rpob
visa
substitut
therefor
aim
examin
rpob
mutat
mrsa
isol
thai
univers
hospit
method
ten
mrsa
isol
classifi
vancomycin
resist
phenotyp
use
popul
analysi
profil
area
curv
papauc
method
nucleotid
sequenc
rpob
isol
determin
compar
wild
type
isol
result
mrsa
isol
includ
vssa
hvisa
visa
papauc
rang
respect
sever
isol
contain
rpob
mutat
two
isol
vssa
hvisa
visa
amino
acid
substitut
andor
similar
previous
report
mrsa
isol
sever
countri
includ
thailand
addit
silent
mutat
found
vssa
hvisa
visa
isol
mutat
rpob
found
one
vssa
isol
conclus
mutat
rpob
gene
may
relat
vancomycin
resist
aureu
studi
background
vancomycin
mainli
use
treatment
patient
staphylococcu
aureu
infect
decreas
suscept
vancomycin
becom
increasingli
common
therefor
find
novel
marker
develop
diagnost
tool
vancomycinintermedi
aureu
visa
import
appli
genomewid
associ
approach
discrimin
visa
vancomycinsuscept
aureu
vssa
use
wholegenom
sequenc
clinic
isol
publicli
avail
genom
sequenc
method
vancomycin
suscept
determin
use
agar
dilut
broth
microdilut
etest
strain
mic
three
method
defin
visa
genom
dna
isol
overnight
cultur
use
wizard
genom
dna
purif
kit
genom
sequenc
perform
use
either
illumina
miseq
pacbio
rs
ii
suquenc
appli
qualitycontrol
clean
raw
read
use
prinseq
version
singlenucleotid
polymorph
snp
call
perform
use
samtool
bcftool
function
annot
snp
carri
use
inhous
develop
perl
script
perform
associ
studi
use
plink
softwar
packag
ppf
predict
phenotyp
snp
packag
addon
confirm
snp
associ
visa
phenotyp
use
clustalw
multipl
amino
acid
sequenc
align
result
obtain
snp
associ
visa
phenotyp
among
snp
show
substitut
nonsynonym
amino
acid
snp
show
amino
acid
chang
select
candid
associ
reduc
vancomycin
suscept
among
snp
base
locat
function
analysi
use
clustalw
multipl
sequenc
align
indic
two
novel
snp
possibl
distinguish
vssa
visa
includ
iron
transport
ktrb
conclus
found
two
novel
marker
discrimin
visa
vssa
addit
studi
requir
identifi
function
differ
relat
antibiot
resist
may
result
snp
background
small
coloni
variant
scv
slowgrow
bacteri
subpopul
gener
show
lower
antimicrobi
suscept
wildtyp
wt
strain
report
scv
strain
vancomycinresist
enterococcu
faecium
vref
rare
report
previous
method
two
vref
isol
show
scv
phenotyp
isol
rectal
swab
two
hospit
patient
mlst
pfge
perform
molecular
character
scv
wt
strain
compar
growth
curv
stabil
phenotyp
antimicrobi
suscept
biofilm
form
abil
scv
wt
strain
result
vref
strain
mlst
pfge
pattern
confirm
scv
wt
strain
ident
phenotyp
switch
stabl
even
passag
scv
phenotyp
switch
wt
passag
signific
differ
antimicrobi
suscept
scv
wt
strain
howev
biofilm
format
scv
strain
lower
wt
conclus
two
scv
rectal
isol
show
antimicrobi
suscept
wt
strain
one
scv
strain
stabl
multipl
passag
biofilm
form
abil
high
scv
strain
even
one
scv
show
lower
abil
wt
strain
mrsa
isol
character
multilocu
sequenc
type
mlst
sccmec
type
spa
type
perform
isol
belong
result
seven
differ
st
identifi
frequent
st
follow
account
respect
account
account
among
mrsa
isol
predomin
spa
type
follow
conclus
result
show
st
mrsa
becom
increasingli
isol
clinic
specimen
hospit
patient
korea
wherea
mrsa
becom
decreas
preval
past
decad
identif
helicobact
pylori
water
sourc
makassar
nurul
uleng
chaidir
utami
univers
hasanuddin
makassar
indonesia
introduct
helicobact
pylori
h
pylori
gramneg
microaerophil
spiral
shape
bacterium
colon
human
gastric
mucosa
known
approxim
human
popul
infect
h
pylori
colon
microorgan
major
risk
factor
peptic
ulcer
diseas
gastric
adenocarcinoma
mucoseassoci
lymphoid
tissu
malt
preval
h
pylori
reach
develop
countri
andup
indonesia
infect
ethnic
indonesia
papua
batak
bugi
previou
studi
identifi
relationshipbetween
preval
h
pylori
infect
water
sourc
commun
method
studi
observ
analyt
studi
cross
section
studi
design
purpos
sampl
techniqu
studi
sampl
taken
water
sourc
slum
district
makassar
find
presenc
h
pylori
examin
use
polymeras
chain
reaction
pcr
synthes
dna
fragment
use
posit
control
base
sequenc
glmm
gene
repres
bp
band
electrophoresi
gel
wherea
distil
water
use
neg
control
result
among
water
sampl
taken
slum
district
makassar
h
pylori
detect
bypolymeras
chain
reaction
pcr
conclus
found
contamin
h
pylori
water
sourc
slum
area
makassar
keyword
helicobact
pylori
polymeras
chain
reaction
water
sourc
surveil
studi
japanes
enceph
emerg
infecti
diseas
india
r
kant
yadav
univers
delhi
new
delhi
india
indian
council
medic
research
new
delhi
india
japanes
enceph
formerli
known
japanes
b
enceph
diseas
caus
mosquitoborn
japanes
enceph
viru
jev
jev
viru
famili
flavivirida
part
japanes
enceph
serocomplex
genet
relat
virus
particularli
sever
hors
four
known
infect
human
includ
west
nile
viru
mosquito
culex
tritaeniorhynchu
culex
vishnui
amongst
import
vector
diseas
diseas
preval
southeast
asia
south
asia
east
asia
japanes
enceph
viral
activ
widespread
india
first
evid
presenc
viru
date
back
first
case
report
outbreak
report
differ
part
countri
recent
past
state
union
territori
report
japanes
enceph
incid
annual
incid
rang
death
studi
group
tri
studi
epidemiolog
particular
viral
diseas
data
collect
retriev
public
databas
well
local
public
hospit
across
infect
region
epidemiolog
link
methicillinresist
staphylococcu
aureu
mrsa
colonis
patient
hospit
environ
hm
wong
ty
ng
yy
chua
sengkang
health
alexandra
hospit
singapor
background
mrsa
colonis
subsequ
infect
contribut
significantli
toward
patient
morbid
hospit
environ
potenti
rout
transmiss
hospit
monitor
mrsa
acquisit
rate
screen
patient
upon
admiss
prior
discharg
notic
rise
mrsa
acquisit
rate
hospit
februari
method
screen
patient
hospit
assess
extent
situat
major
male
ward
patient
acquir
mrsa
februari
stay
establish
patient
acquir
mrsa
perform
environment
sampl
analyz
posit
isol
patient
environ
pulsedfield
gel
electrophoresi
pfge
result
strain
mrsa
found
patient
curtain
day
room
chair
anoth
patient
curtain
mrsa
genet
similar
strain
figur
empti
ward
termin
clean
step
daili
target
clean
hightouch
surfac
curtain
chang
although
number
mrsa
colonis
patient
decreas
march
still
patient
colonis
mrsa
ward
despit
measur
taken
took
cultur
environ
found
aircool
filter
ward
ident
mrsa
strain
first
cluster
februari
figur
thorough
clean
filter
environ
patient
ward
baselin
found
colonis
subsequ
month
conclus
confirm
epidemiolog
link
mrsa
colonis
patient
hospit
environ
pseudooutbreak
use
pfge
presenc
stringent
infect
control
measur
meticul
clean
hightouch
surfac
common
area
crucial
prevent
nosocomi
transmiss
mrsa
via
hospit
environ
knowledg
relat
use
antibiot
univers
sri
lanka
np
senanayak
v
navaratn
balasuriya
faculti
medicin
gener
sir
john
kotelawala
defenc
univers
sri
lanka
introduct
inappropri
use
antibiot
worldwid
phenomenon
occur
especi
develop
worldand
lead
develop
resist
antibiot
object
aim
studi
evalu
knowledg
relat
use
antibiot
among
preclin
clinic
student
faculti
medicin
gener
sir
john
kotelawala
defenc
univers
sri
lanka
methodolog
selfadminist
pretest
valid
questionnair
previou
public
use
data
collect
questionnair
base
knowledg
relat
use
antibiot
wasdistribut
among
medic
student
result
analyz
compar
knowledg
preclin
clinic
studentsat
thefaculti
medicin
gener
sir
john
kotelawaladef
univers
percentag
calcul
compar
use
z
test
proport
p
valu
consid
statist
signific
result
age
rang
particip
year
male
preclin
clinic
student
percentag
preclin
student
knew
antibiot
use
suspect
bacteri
infect
antibiot
start
doctor
prescript
import
correct
durat
antibiot
use
import
correct
dosag
interv
antibiot
use
respect
percentag
clinic
student
knew
antibiot
use
suspect
bacteri
infect
antibiot
start
doctor
prescript
import
correct
durat
antibiot
use
import
correct
dosag
interv
antibiot
use
respect
signific
p
valu
differ
two
group
respect
preclin
student
knew
frequent
inappropri
antibiot
use
could
lead
develop
antibiot
resist
clinic
student
knew
frequent
inappropri
use
antibiot
would
lead
develop
antibiot
resist
df
p
conclus
knowledg
relat
use
antibiot
better
among
clinic
student
comparison
preclin
student
background
control
prevent
methicillinresist
staphylococcu
aureu
mrsa
transmiss
healthcar
remain
signific
challeng
worldwid
one
main
emphasi
promot
hand
hygien
practic
among
healthcar
worker
howev
role
patient
contact
nosocomi
transmiss
mrsa
unclear
aim
studi
evalu
contact
method
prospect
observ
studi
mrsaposit
patient
mrsaneg
patient
admit
institut
march
decemb
episod
patienttopati
contact
patienttoenviron
contact
hand
hygien
practic
observ
record
associ
key
exposur
variabl
contact
episod
hand
hygien
practic
analyz
result
patienttopati
contact
episod
environment
contact
episod
observ
observ
hour
median
contact
episod
per
subject
patient
zone
common
healthcar
zone
respect
common
point
contact
bedrail
bedsid
tabl
toilet
door
handl
statist
signific
differ
contact
pattern
mrsaposit
mrsaneg
patient
among
patient
function
independ
assist
mrsaposit
patient
contact
episod
healthcar
zone
compar
mrsaneg
patient
mrsaposit
patient
perform
hand
wash
compar
among
mrsaneg
patient
conclus
direct
patient
contact
share
environ
patient
infrequ
hand
hygien
practic
among
mrsa
patient
could
play
role
nosocomi
transmiss
mrsa
introduct
antimicrobi
resist
amr
emerg
problem
develop
develop
countri
philippin
mdh
activ
join
global
effort
fight
amr
sinc
studi
aim
assess
initi
impact
asp
preval
mdro
antibiot
consumpt
measur
defin
daili
dose
methodolog
review
surveil
data
antibiot
usag
done
specimen
posit
k
pneumonia
kpc
e
coli
k
pneumonia
esbl
methicillinresist
aureu
mrsa
examin
preval
rate
comput
mdro
per
year
age
sex
length
hospit
stay
gather
util
cefepim
ertapenem
meropenem
imipenem
vancomycin
piptazo
levofloxacin
ciprofloxacin
comput
patientday
differ
antibiot
consumpt
program
implement
evalu
use
ttest
spearman
correl
use
test
relationship
resist
antibiot
use
result
mean
age
patient
patient
male
patient
icu
longer
length
stay
patient
station
among
isol
mdro
isol
k
pneumonia
esbl
piptazo
ddd
patientday
meropenem
patientday
highest
consumpt
among
monitor
restrict
antibiot
respect
strong
correl
resist
e
coli
use
cefepim
r
p
conclus
increas
util
cefepim
correl
resist
e
coli
agent
sinc
asp
recent
implement
true
impact
asp
may
evid
time
evalu
moreov
although
subject
latent
tb
infect
ltbi
asymptomat
infecti
may
eventu
develop
activ
diseas
thu
screen
treatment
ltbi
import
fundament
tool
tb
control
program
hcw
object
studi
assess
preval
epidemiolog
characterist
ltbi
among
hcw
hospit
seoul
south
korea
method
crosssect
studi
hcw
conduct
particip
administ
questionnair
demograph
exclud
hcw
histori
tb
ltbi
treatment
studi
quantiferon
tbgold
qft
assay
perform
screen
hcw
work
konkuk
univers
medic
center
korea
epidemiolog
risk
factor
ltbi
identifi
logist
regress
analysi
result
preval
posit
qft
signific
associ
risk
factor
sex
work
medic
domain
employ
type
posit
qft
howev
work
medic
domain
tend
posit
qft
work
surgic
domain
vs
p
ci
higher
age
year
old
significantli
associ
posit
qft
ci
p
qft
posit
hcw
refer
chest
xray
examin
pulmonolog
specialist
none
found
activ
tb
thu
diagnos
ltbi
conclus
find
suggest
preval
ltbi
hcw
may
rel
high
risk
ltbi
increas
longer
work
experi
result
activ
serial
screen
ltbi
need
hcw
introduct
improp
practic
lack
knowledg
food
handler
contribut
factor
spread
foodborn
outbreak
studi
aim
explor
knowledg
attitud
practic
foodhand
hygien
observ
hand
wash
practic
among
food
handler
gener
sir
john
kotelawala
defenc
univers
kdu
kdu
guest
hous
methodolog
descript
cross
section
studi
done
among
food
handler
involv
food
product
possess
distribut
gener
sir
john
kotelawala
defenc
univers
kdu
guest
hous
inform
gather
method
use
pretest
valid
questionnair
direct
observ
use
data
collect
associ
test
handfood
hygien
knowledgeattitud
categori
servic
chef
cook
kitchen
assist
waiter
other
includ
food
distribut
staff
level
educ
complet
primari
educ
grade
complet
gce
ol
complet
gce
al
durat
servic
work
year
year
less
year
result
food
handler
excel
knowledg
food
hygien
categori
servic
level
educ
food
handler
relat
knowledg
attitud
food
hygien
p
howev
signific
differ
knowledg
food
hygien
durat
servic
employe
p
knowledg
attitud
hand
hygien
excel
food
handler
except
knowledg
step
hand
wash
techniqu
p
direct
observ
observ
food
handler
hand
wash
practic
significantli
relat
place
work
kdu
kdu
guest
hous
categori
servic
p
conclus
food
handler
gener
sir
john
kotelawala
defenc
univers
good
knowledg
attitud
practic
regard
food
hand
hygien
educ
train
program
necessari
improv
knowledg
attitud
practic
food
hand
hygien
background
activ
surveil
cultur
carbapenemresist
enterobacteriacea
asccr
recommend
highrisk
set
aim
investig
effect
ast
patient
admit
intens
care
unit
icu
risk
factor
cre
acquisit
method
prospect
conduct
asccr
rectal
swab
patient
admit
icu
tertiari
hospit
south
korea
asccr
done
admiss
retest
weekli
asccr
perform
cdc
method
pcr
assay
perform
detect
carbapenemas
gene
ndm
kpc
vim
imp
oxa
result
total
patient
admit
studi
period
cre
acquisit
rate
carbapenemaseproduc
enterobacteriacea
cpe
invas
infect
found
common
speci
klebsiella
pneumonia
kpc
ndm
gene
detect
creposit
patient
inhospitalmort
higher
p
multivari
analys
show
prior
exposur
healthcar
facil
outpati
visit
admiss
surgeri
preced
year
aor
ci
cocolon
multidrugresist
organ
mdro
aor
ci
length
admiss
cre
detect
day
ci
independ
associ
cre
acquisit
conclus
use
asccr
cre
acquisit
rate
prior
exposur
healthcar
facil
cocolon
mdro
length
admiss
cre
detect
day
risk
factor
cre
acquisit
background
nation
surveil
system
prove
reduc
deviceassoci
infect
dai
sever
studi
mani
countri
alreadi
appli
therefor
investig
time
trend
dai
rate
factor
associ
chang
trend
year
korean
nation
healthcareassoci
infect
surveil
system
koni
method
investig
dai
rate
koni
particip
intens
care
unit
icu
hospit
dai
rate
calcul
number
infect
per
deviceday
data
associ
icu
characterist
collect
mix
linear
regress
analysi
use
statist
analysi
result
rate
ventil
associ
pneumonia
vap
significantli
decreas
per
ventilatorday
f
p
also
rate
cathet
associ
urinari
tract
infect
cauti
cline
associ
blood
stream
infect
clbsi
significantli
decreas
per
catheterday
f
p
per
catheterday
f
p
subgroup
analysi
rate
vap
cauti
clbsi
significantli
decreas
regardless
organiz
institut
characterist
icu
conclus
korea
dai
shown
signific
reduct
last
year
might
associ
particip
surveil
koni
need
encourag
particip
hospit
keyword
deviceassoci
infect
yearwis
trend
surveil
intens
care
unit
antibiogram
south
indian
hospit
myth
realiti
dr
sureshkumar
dr
k
divya
dr
soujanya
apollo
hospit
chennai
sim
hospit
vadapalani
chennai
object
period
analysi
report
antimicrobi
suscept
antibiogram
effect
improv
antibiot
prescrib
practic
hospit
intern
societi
recommend
institut
antibiogram
help
better
implement
antibiot
stewardship
activ
hospit
littl
known
indian
hospit
compel
antibiogram
aim
studi
studi
describ
key
featur
hospit
antibiogram
south
indian
hospit
method
use
crosssect
research
design
purpos
sampl
accredit
hospit
across
south
india
conduct
use
structur
questionnair
prepar
base
latest
clsi
antibiogram
guidelin
content
valid
survey
questionnair
carri
infecti
diseas
physician
postdoctor
fellow
survey
questionnair
complet
consent
respond
infect
control
team
member
microbiolog
laboratori
personnel
either
facetofac
interact
telephon
interview
taken
analysi
data
compil
use
descript
statist
result
contact
respond
complet
survey
paramet
survey
shown
tabl
contributori
begin
juli
septemb
increas
ssi
obstetr
gynaecolog
og
note
aim
evalu
ssi
case
potenti
caus
cluster
measur
periop
antimicrobi
appropri
develop
intervent
reduc
ssi
improv
appropri
periop
antimicrobi
use
method
data
ssi
case
collect
describ
subsequ
employ
plandostudyact
pdsa
methodolog
result
discuss
use
develop
intervent
togeth
stakehold
structur
chang
suggest
implement
repeat
review
chang
perform
measur
process
track
addit
ssi
trend
result
confirm
increas
ssi
baselin
tempor
spatial
cluster
obes
receiv
periop
antibiot
within
min
incis
receiv
appropri
type
dose
antibiot
receiv
chlorhexidinealcohol
surgic
skin
antisepsi
obstetr
case
occur
day
postop
suggest
multipl
possibl
caus
work
multipl
stakehold
bundl
intervent
develop
best
practic
implement
also
rectifi
downtim
form
use
junior
doctor
prescrib
periop
antibiot
erron
end
march
total
ssi
rate
decreas
see
figur
ssi
patient
receiv
time
periop
antibiot
receiv
chlorhexidinealcohol
surgic
skin
antisepsi
though
ssi
case
receiv
appropri
type
dose
periop
antibiot
conclus
continu
engag
key
stakehold
critic
implement
chang
ensur
buyin
time
improv
outcom
often
requir
process
well
structur
improv
outcom
bundl
measur
may
effect
intervent
current
epidemiolog
reveal
divers
distribut
fungal
isol
one
centr
anoth
may
influenc
clinic
practic
manag
mycos
studi
undertaken
describ
distribut
fungal
isol
new
clinic
train
centr
malaysia
ninetythre
fungal
isol
specimen
detect
saboraud
dextros
agar
brain
heart
infus
media
januari
march
identif
isol
perform
assess
coloni
morpholog
microscopi
examin
major
fungi
isol
nail
n
follow
skin
scrap
blood
bronchioalveolar
lavag
tissu
biopsi
respect
commonli
isol
fungi
consist
nonalbican
candida
follow
candida
albican
fusarium
spp
trichophyton
spp
aspergillu
spp
trichosporon
spp
cladosporium
spp
sporothrix
schenkii
rhizopu
spp
penicillium
spp
contribut
isol
fungi
verruconi
gallopava
cryptococcu
laurentii
bipolari
spp
curvularia
spp
acremonium
spp
chaetomium
spp
microsporum
spp
ad
distribut
candida
albican
remain
common
isol
fungi
follow
fusarium
spp
trichophyton
spp
three
isol
mainli
isol
blood
skin
scrap
nail
emphasi
need
continu
surveil
regard
distribut
fungal
isol
need
carri
provid
resourc
inform
commenc
empir
antifung
therapi
aim
studi
produc
fluconazoleload
liposom
nanoparticl
analyz
physicochem
properti
compar
antifung
effect
free
fluconazol
drug
vitro
fluconazol
suscept
resist
candida
speci
isol
patient
six
common
candida
speci
includ
c
albican
c
parapsilosi
c
tropicali
c
glabrata
c
krusei
c
guilliermondii
test
liposom
nanoparticl
prepar
use
thinlay
hydrat
method
soybean
lecithin
cholesterol
fluconazol
ratio
nanoparticl
analyzedin
term
size
poli
dispers
index
zeta
potenti
morpholog
entrap
effici
drug
amount
drug
releas
investig
antifung
effect
liposom
nanoparticl
compar
free
form
fluconazol
use
broth
microdilut
describ
clsi
result
analyz
use
student
ttest
indic
greater
antifung
effect
liposom
nanoparticl
contain
fluconazol
normal
form
drug
shown
mic
fluconazol
put
rang
sensit
speci
exposur
fluconazol
nanoliposom
fluconazoleresist
candida
speci
except
krusei
speci
object
candida
bloodstream
infect
bsi
associ
signific
morbid
mortal
patient
hematolog
malign
howev
issu
whether
central
venou
cathet
cvc
remov
remain
controversi
especi
neutropen
patient
method
prospect
observ
studi
adult
patient
hematolog
malign
develop
candida
bsi
cvc
place
cvc
remov
prefer
nonneutropen
patient
neutropen
patient
sourc
presum
cvc
fail
show
candida
clearanc
bloodstream
despit
appropri
antifung
therapi
result
patient
candida
bsi
neutropen
nonneutropen
overal
cvc
remov
patient
time
point
cvc
less
frequent
remov
neutropen
patient
nonneutropen
patient
vs
p
differ
mortal
rate
week
follow
cvc
remov
cvc
retent
vs
p
independ
predictor
mortal
refractori
neutropenia
pitt
bacteremia
score
differ
demograph
clinic
characterist
cvc
remov
retent
group
mortal
neutropen
patient
candida
bsi
differ
cvc
remov
retent
group
vs
p
oral
candida
isol
collect
patient
misrata
libya
characteris
use
vitek
compact
system
result
preval
speci
includ
c
albican
c
glabrata
c
dubliniensi
c
krusei
c
tropicali
c
sake
c
kefyr
c
guilliermondii
c
parapsilopsi
c
membranifacien
c
magnolia
drug
suscept
show
emerg
resist
across
repres
speci
breakpoint
avail
except
c
parapsilopsi
although
establish
interpret
breakpoint
speci
three
c
sake
isol
c
membranifacien
isol
also
high
mic
valu
fluconazol
test
isol
found
larg
suscept
caspofungin
micafungin
c
albican
isol
suscept
echinocandin
amphotericin
b
resist
one
drug
class
seen
c
dubliniensi
c
glabrata
c
krusei
isol
conclus
although
suscept
result
echinocandin
encourag
resist
azol
appar
ignor
especi
case
fluconazol
often
local
avail
antifung
drug
treatment
dissemin
candidiasi
current
live
vaccin
toxovax
produc
attenu
varieti
toxoplasma
gondii
aim
studi
evalu
immunogen
live
varieti
gondii
produc
serial
passag
cell
cultur
twentyfour
balbc
mice
randomli
divid
three
group
group
neg
control
receiv
cell
cultur
media
group
ii
posit
control
iii
inocul
acut
razi
strain
gondii
respect
mice
assess
daili
potenti
mortal
record
twentyeight
day
later
blood
sampl
collect
group
elisa
mice
challeng
inject
acut
strain
gondii
result
show
control
group
mortal
start
day
day
challeng
mice
group
die
posit
control
group
like
first
group
day
challeng
mortal
start
day
mice
die
interest
find
mortal
rate
third
group
result
suggest
razi
varieti
gondii
caus
partial
immun
mice
varieti
nt
caus
diseas
mortal
mice
aim
studi
establish
attenu
neospora
caninum
tachyzoit
serial
passag
cell
line
virul
attenu
tachyzoit
balbc
mice
also
evalu
isol
passag
time
cell
line
produc
high
passag
attenu
strain
total
femal
balbc
mice
averag
age
week
randomli
separ
seven
group
first
group
control
inocul
subcutan
cell
cultur
media
second
third
fourth
group
receiv
low
passag
acut
strain
differ
dose
tachyzoit
three
group
inocul
high
passag
tachyzoit
similar
dose
mortal
rate
patholog
chang
group
note
daili
cellular
humor
immun
assess
skin
test
elisa
respect
result
present
studi
show
mice
group
receiv
high
passag
strain
surviv
show
patholog
chang
neosporosi
addit
cellular
humor
immun
respons
n
caninum
significantli
higher
mice
receiv
high
passag
tachyzoit
background
popul
egypt
chronic
hepat
c
hcv
genotyp
aim
present
studi
earli
predic
efficaci
hcv
treatment
sofosbuvir
sovaldi
compar
antivir
efficaci
dual
plu
ribavirin
rbv
tripl
plu
pegyl
interferon
pegifn
rbv
sovaldi
combin
therapi
method
blood
sampl
patient
chronic
infect
hcv
genotyp
differ
egyptian
healthi
center
use
dna
extract
singl
nucleotid
polymorph
snp
genotyp
snp
genotyp
interferon
gene
perform
taqman
probe
assay
rtpcr
hcvrna
carri
start
end
treatment
twelv
twenti
four
week
end
treatment
hepat
b
viru
hbv
infect
global
concern
estim
world
popul
infect
malaysia
nation
seropreval
rate
categoris
hbv
intermedi
endem
countri
howev
rate
repres
data
smallest
ethnic
minor
indigen
peopl
orang
asli
henc
object
studi
determin
hbv
seropreval
rate
among
orang
asli
malaysia
cross
section
studi
involv
negrito
smallest
group
three
main
orang
asli
tribe
studi
conduct
five
differentlyloc
negrito
settlement
one
hundr
fifti
particip
recruit
consent
interview
physic
examin
blood
investig
sera
test
hepat
b
surfac
antigen
hbsag
use
hbsag
ii
assay
demograph
data
biolog
well
biochem
paramet
eventu
analys
use
spss
version
spss
chicago
il
usa
particip
test
posit
hbsag
give
overal
hbv
preval
rate
ci
male
femal
ratio
almost
eight
male
five
femal
infect
major
infect
year
old
born
mother
screen
hbv
antenat
almost
half
n
past
histori
tattoo
bodi
pierc
conclus
hbv
preval
rate
among
orang
asli
almost
thrice
malaysia
nation
rate
compar
studi
conduct
indigen
popul
elsewher
possibl
rout
transmiss
popul
either
vertic
transmiss
well
practic
tattoo
bodi
pierc
background
dengu
case
malaysia
common
still
rise
due
right
climat
variabl
high
temperatur
copiou
rainfal
addit
human
activ
toward
urban
malaysia
classifi
endem
countri
dengu
monsoon
season
fall
novemb
march
june
septemb
year
patient
acut
febril
ill
typic
atyp
present
diagnos
suspect
dengu
proven
otherwis
aim
studi
determin
correl
occurr
suspect
dengu
case
chang
climat
urban
area
west
malaysia
methodolog
retrospect
data
collect
uitm
sungai
buloh
clinic
train
centr
patient
clinic
histori
suspect
dengu
fever
analyz
number
suspect
dengu
fever
year
tabul
match
distribut
rainfal
west
malaysia
result
peak
suspect
dengu
case
januari
juli
respect
coincid
two
monsoon
season
howev
suspect
dengu
case
peak
march
increas
second
monsoon
season
year
figur
period
suspect
dengu
case
februari
may
septemb
decemb
respect
period
minimum
rainfal
drier
climat
conclus
find
show
peak
distribut
suspect
dengu
case
present
centr
correl
well
monsoon
season
howev
period
absenc
suspect
dengu
case
rais
question
whether
malaysia
true
endem
countri
dengu
background
nontyp
haemophilu
influenza
nthi
signific
human
respiratori
pathogen
common
caus
otiti
media
sinus
bronchiti
chronic
obstruct
pulmonari
diseas
nthi
capabl
form
biofilm
may
one
import
factor
contribut
chronic
diseas
acceler
antibiot
resist
resist
bacteria
within
biofilm
convent
antimicrobi
current
major
obstacl
effect
medic
treatment
global
scale
discoveri
develop
new
agent
effect
treatment
nthi
biofilm
therefor
necessari
urgent
need
method
studi
variou
antimicrobi
peptid
synthes
antibiofilm
activ
strong
biofilmform
strain
nthi
investig
microtit
plate
biofilm
assay
result
upon
treatment
test
peptid
modif
nthi
biofilm
format
observ
differ
degre
among
peptid
test
peptid
exhibit
potent
antibiofilm
activ
mean
minimum
biofilm
inhibitori
concentr
appear
result
indic
peptid
power
inhibitori
activ
nthi
biofilm
warrant
investig
applic
peptid
novel
therapeut
agent
control
nthi
biofilmassoci
infect
vitro
pharmacokineticspharmacodynam
antibacteri
moxalactam
extendedspectrum
enterobacteriacea
c
background
limit
choic
drug
treatment
infect
caus
extendedspectrum
esbl
produc
major
clinic
problem
object
method
object
studi
evalu
pharmacodynam
moxalactam
mox
cefotaxim
ctx
cefoperazonesulbactam
cfzsbt
esblproduc
e
coli
k
pneumonia
nonesblproduc
e
coli
use
vitro
pharmacokineticspharmacodynam
pkpd
simul
model
result
nonesblproduc
e
coli
dose
regimen
exhibit
rapid
bactericid
efficaci
regimen
achiev
mic
result
reduct
bacteri
count
log
cfuml
h
test
esblproduc
e
coli
k
pneumonia
ctx
cfzsbt
display
weak
bactericid
effect
subsequ
regrowth
evid
contrast
mox
continu
achiev
reduct
bacteri
count
log
cfuml
h
mox
g
iv
eventu
achiev
log
cfuml
reduct
h
requir
mic
esbl
produc
higher
nonesblproduc
isol
conclus
mox
could
serv
altern
bactericid
agent
esbl
produc
vitro
pharmacokineticspharmacodynam
evalu
fosfomycin
combin
amikacin
colistin
klebsiella
pneumonia
w
yu
p
shen
z
object
emerg
carbapenemresist
enterobacteriacea
especi
klebsiella
pneumonia
becom
major
concern
clinic
set
combin
therapi
gain
momentum
counter
secondari
resist
potenti
suboptim
efficaci
monotherapi
aim
studi
evalu
bactericid
effect
fosfomycin
fm
amikacin
amk
colistin
col
alon
combin
k
pneumonia
use
dynam
model
simul
human
pharmacokinet
vitro
method
pharmacokinet
auto
simul
system
system
employ
simul
differ
dose
regimen
fm
amk
col
alon
combin
bacteri
growth
recoveri
time
rt
area
control
growth
antibacteri
kill
curv
ie
use
unbias
comprehens
mean
determin
antimicrobi
effect
result
observ
col
alon
much
pronounc
fm
amk
kpckp
ie
fm
g
everi
hour
plu
amk
mgkg
oncedaili
fm
g
everi
hour
plu
col
iukg
everi
hour
higher
respect
monotherapi
sensit
strain
note
rate
resist
lower
use
combin
fm
g
everi
hour
plu
col
iukg
everi
hour
use
col
iukg
everi
hour
alon
conclus
combin
fm
g
everi
hour
plu
amk
mgkg
oncedaili
fm
g
background
although
carbapenem
remain
effect
treat
seriou
multidrugresist
p
aeruginosa
infect
carbapenemresist
p
aeruginosa
crpa
emerg
dissemin
worldwid
ceftolozanetazobactam
ct
demonstr
activ
mani
multidrugresist
isol
evalu
activ
ct
compar
activ
ceftazidim
avibactam
ca
use
wellcharacter
collect
crpa
isol
method
fiftyseven
crpa
isol
previou
studi
includ
isol
previous
evalu
presenc
bla
imp
bla
vim
bla
spm
bla
gim
bla
sim
bla
kpc
pcr
express
oprd
ampc
sever
efflux
pump
gene
also
investig
qrtpcr
antimicrobi
suscept
ct
well
ca
test
broth
microdilut
follow
clinic
laboratori
standard
institut
clsi
guidelin
clsi
suscept
breakpoint
ct
fda
suscept
breakpoint
ca
ml
appli
result
fifteen
isol
includ
isol
bla
bla
show
mic
mgl
ct
ca
among
carbapenemas
nonproduc
crpa
isol
overal
suscept
ct
compar
ca
ceftazidim
piperacillintazobactam
meropenem
cefepim
respect
total
carbapenemas
nonproduc
crpa
isol
show
oprd
loss
whilst
isol
overexpress
one
gene
efflux
system
ampc
interestingli
ct
mic
valu
mutant
strain
except
three
isol
low
mic
valu
ct
rang
median
isol
overexpress
ampc
wherea
isol
basal
ampc
express
level
mic
valu
rang
slightli
lower
median
mic
valu
conclus
ct
activ
larg
percentag
noncarbapenemas
produc
crpa
asid
isol
acquir
carbapenemas
appar
correl
ct
mic
valu
specif
mutationdriven
resist
mechan
among
crpa
elucid
method
cover
gastric
mucou
layer
two
group
ten
rat
administ
either
smectit
sgm
evalu
antih
pylori
efficaci
mice
divid
group
h
pylori
erad
assess
campylobacterlik
organ
clo
test
h
pylori
pcr
gastric
mucosa
h
pylori
antigen
pcr
mous
fece
level
proinflammatori
cytokin
examin
result
sgm
retain
gastric
mucos
layer
distribut
ratio
h
sgmbase
tripl
regimen
decreas
bacteri
burden
vivo
compar
untreat
mice
mice
treat
regimen
therapeut
reaction
clo
test
h
pylori
pcr
gastric
mucosa
group
iiiviii
respect
h
pylori
pcr
fece
mice
group
iii
group
v
respect
sgm
tripl
therapi
also
reduc
level
proinflammatori
cytokin
conclus
result
suggest
sgm
promis
effect
therapeut
agent
treatment
h
pylori
infect
antimicrobi
activ
pseudomona
sp
strain
broad
spectrum
pathogen
bacteria
fungi
magdalena
shirley
faculti
biotechnolog
atma
jaya
cathol
univers
indonesia
jalan
jender
sudirman
jakarta
indonesia
use
untreat
water
drink
activ
like
aquacultur
associ
infect
human
aim
studi
examin
potenti
activ
pseudomona
sp
strain
pathogen
microorgan
determin
physiolog
biochem
characterist
antimicrobi
compound
agarwel
diffus
method
use
detect
antimicrobi
activ
strain
pseudomona
sp
show
broad
inhibit
spectrum
activ
variou
pathogen
bacteria
fungi
supernat
show
inhibitori
activ
obtain
grown
rang
ph
temperatur
physicochem
character
antimicrobi
activ
show
stabl
activ
preserv
wide
rang
ph
antagonist
activ
observ
indic
strain
possess
due
proteas
amylas
produc
strain
suggest
studi
address
use
pseudomona
sp
strain
novel
antimicrobi
treat
infecti
diseas
multidrugresist
phenotyp
esblsproduc
enterobacteriacea
isol
anim
origin
high
alert
veterinari
hospit
p
kongsanan
weerakhun
pradidruengchan
p
jarupach
antimicrobi
resist
bacteri
pathogen
human
anim
origin
becom
main
problem
global
public
health
concern
use
antimicrobi
agent
anim
hospit
increas
select
pressur
risk
spread
antibiot
resist
bacteria
human
commun
determin
occurr
resist
phenotyp
routin
bacteri
cultur
privat
veterinari
hospit
bangkok
novemb
may
total
gram
neg
bacteri
isol
variou
type
infect
differ
speci
anim
test
antimicrobi
suscept
test
antibiogram
show
ampicillin
resist
antibiot
follow
norfloxacin
enrofloxacin
marbofloxacin
multidrugresist
mdr
phenotyp
shown
isol
acinetobact
baummanii
escherichia
coli
proteu
mirabili
klebsiella
pneumonia
pseudomona
aeruginosa
respect
among
enterobacteriacea
isol
p
mirabili
k
pneumonia
e
coli
isol
exhibit
esblsproduc
phenotyp
frequenc
multidrugresist
phenotyp
esblsproduc
phenotyp
alarm
studi
show
anim
privat
veterinari
hospit
import
reservoir
mdr
bacteria
consequ
continu
monitor
antimicrobi
suscept
pattern
veterinari
hospit
requir
furthermor
major
dissemin
resist
bacteria
commun
may
unavoid
prevent
measur
place
inform
use
establish
antimicrobi
control
polici
anim
practic
minim
emerg
mdr
bacteria
background
respiratori
ill
one
signific
diseas
influenc
health
industri
pig
pasteurella
multocida
streptococcu
sui
secondari
invad
caus
swine
respiratori
diseas
aim
studi
investig
recent
preval
p
multocida
sui
character
antimicrobi
suscept
isol
lung
pig
slaughterhous
korea
method
total
lung
sampl
patholog
lesion
obtain
two
slaughterhous
decemb
juli
lung
sampl
asept
plate
blood
agar
incub
co
incub
h
presumpt
isol
p
multocida
sui
confirm
pcr
minimum
inhibitori
concentr
mic
p
multocida
sui
antimicrobi
agent
determin
accord
clsi
guidelin
result
total
p
multocida
sui
isol
lung
pig
p
multocida
isol
suscept
neomycin
ampicillin
penicillin
spectinomycin
wherea
resist
trimethoprimsulfamethoxazol
florfenicol
oxytetracyclin
tylosin
sulfadimethoxin
chlortetracyclin
second
follow
tetracyclin
tilmicosin
sui
isol
show
resist
tilmicosin
oxytetracyclin
second
follow
enrofloxacin
florfenicol
danofloxacin
tetracyclin
tulathromycin
chlotetracyclin
tylosin
erythromycin
conclus
studi
recent
preval
p
multocida
sui
detect
overal
differ
mic
resist
pattern
accord
antimicrobi
use
antimicrobi
food
anim
monitor
regularli
minim
emerg
resist
bacteria
case
multipl
abcess
due
melioidosi
first
case
report
north
sumatera
indonesia
ap
pasaribu
pasaribu
melioidosi
emerg
zoonosi
caus
highli
invas
drug
resist
bacterium
name
burkholderia
pseudomallei
found
soil
endem
southeast
asia
pacif
region
b
pseudomallei
exhibit
resist
divers
antibiot
remain
sensit
third
gener
cephalosporin
carbapenem
fluoroquinolon
indonesia
case
underreport
due
unawar
sinc
mimic
mani
diseas
case
indonesia
report
dutch
literatur
export
case
western
countri
case
boy
refer
pediatr
ward
treat
surgeri
ward
week
due
recurr
abscess
back
thought
spondyl
tuberculosi
tuberculosi
workup
neg
boy
use
play
footbal
mud
swim
river
lesion
start
small
pustul
grown
size
within
month
abscess
drainag
treat
cours
levofloxacin
unfortun
lesion
persist
subfebril
fever
found
month
dri
cough
month
develop
pale
decreas
bodi
weight
month
liver
spleen
enlarg
found
pu
cultur
yield
burkholderia
pseudomallei
patient
treat
ceftazidim
sulfamethoxazoletrimethoprim
week
continu
oral
sulfamethoxazoletrimethoprim
period
month
condit
improv
significantli
follow
regularli
report
first
case
melioidosi
north
sumatera
indonesia
patient
treat
ceftazidim
sulfamethoxazoletrimethoprim
month
symptom
well
improv
use
plasma
exchang
follow
convalesc
plasma
therapi
critic
ill
patient
sever
fever
thrombocytopenia
syndromeassoci
encephalopathi
yearold
boy
present
fever
cough
juli
patient
diagnos
langerhan
cell
histiocytosi
day
old
treat
vinblastin
methotrex
blood
test
reveal
pancytopenia
blood
cultur
posit
nontyphoid
salmonella
nt
serogroup
nt
isol
detect
blood
n
stool
n
specimen
episod
fever
diarrhea
observ
may
identifi
seoul
research
institut
public
health
environ
salmonella
enterica
serovar
enteritidi
initi
salmonella
infect
treat
mainli
ceftriaxon
resolv
first
salmonella
enteritidi
isol
stool
detect
six
month
first
detect
januari
blood
first
isol
juli
blood
suscept
ceftazidim
cefotaxim
cotrimoxazol
intermedi
levofloxacin
resist
ampicillin
isol
blood
remain
suscept
gener
cephalosporin
salmonella
isol
start
detect
stool
specimen
antibiogram
isol
blood
stool
ident
stool
isol
resist
drug
test
includ
gener
cephalosporin
except
levofloxacin
stool
isol
show
synerg
use
amoxicillinclavulan
disk
pcr
posit
bla
ctxm
sequenc
analysi
show
bla
cefotaxim
resist
transfer
conjug
pfge
xbaidigest
chromosom
dna
show
blood
isol
ident
pattern
four
stool
isol
differ
pattern
band
differ
conclus
repeat
isol
salmonella
enteritidi
ident
pfge
pattern
blood
immunocompromis
patient
indic
difficulti
erad
intracellular
salmonella
salmonella
enteritidi
stool
isol
band
differ
note
suggest
clonal
stool
isol
esbl
could
acquir
bla
carri
plasmid
intestin
flora
invas
pulmonari
aspergillosi
follow
sever
commun
acquir
adenoviru
pneumonia
hm
wong
yy
chua
singapor
gener
hospit
singapor
background
adenoviru
common
pathogen
upper
respiratori
tract
infect
commun
acquir
pneumonia
cap
infect
often
selflimit
sever
ill
occur
immunocompromis
host
rare
case
sever
adenoviru
pneumonia
immunocompet
adult
report
gener
poor
outcom
invas
pulmonari
aspergillosi
ipa
follow
adenoviru
pneumonia
rare
describ
unlik
ipa
occur
influenza
infect
increasingli
recogn
entiti
late
critic
ill
patient
requir
extracorpor
membran
oxygen
ecmo
also
deem
emerg
risk
factor
ipa
method
herein
describ
patient
ipa
follow
sever
cap
due
adenoviru
requir
ecmo
result
male
diabet
mellitu
admit
cap
whose
symptom
start
week
ago
day
admiss
progress
rapidli
acut
respiratori
distress
syndrom
ard
cap
treatment
need
inotrop
support
mechan
ventil
ecmo
polymeras
chain
reaction
test
done
endotrach
aspir
sampl
posit
adenoviru
along
broad
spectrum
antibiot
receiv
day
hydrocortison
cycl
weekli
intraven
cidofovir
sever
adenoviru
pneumonia
relat
ard
ecmo
wean
day
later
remain
ventil
inotrop
depend
week
stop
ecmo
coupl
increas
inflammatori
marker
comput
topographi
chest
done
reveal
air
crescent
sign
suggest
ipa
confirm
fungal
cultur
pleural
fluid
ipsilater
side
clinic
statu
continu
deterior
despit
aspergillosi
treatment
demis
eventu
conclus
ipa
consid
nonimmunocompromis
host
set
sever
adenoviru
pneumonia
requir
ecmo
support
may
potenti
risk
factor
report
trichosporon
fungemia
among
immunocompet
host
without
malign
hematolog
diseas
extrem
rare
report
unexpect
fatal
case
trichosporon
asahii
fungemia
due
multipl
soft
tissu
abscess
occur
immunocompet
patient
without
known
immunocompromis
condit
man
admit
hospit
due
pain
swell
febril
sensat
leg
last
week
ct
lower
extrem
show
numer
tini
fluid
collect
diffus
subcutan
fat
infiltr
whole
leg
empir
iv
unasyn
treatment
clinic
cours
improv
trichosporon
asahii
isol
blood
multipl
wound
cultur
iv
fluconazol
start
laboratori
examin
detect
hidden
autoimmun
diseas
hematolog
diseas
extens
check
figur
abstract
chang
viral
rna
load
igg
ifa
titer
time
therapi
csf
cerebrospin
fluid
sftsv
sever
fever
thrombocytopenia
syndrom
viru
signific
diagnosi
defin
spite
orthoped
manag
iv
antifung
therapi
condit
improv
die
due
uncontrol
sever
septic
shock
rd
hospit
day
trichosporon
speci
isol
blood
cultur
immunocompet
patient
consid
contamin
usual
consid
meaningless
find
mani
physician
howev
trichosporon
speci
caus
sever
fatal
infect
patient
without
immunocompromis
condit
like
case
great
caution
might
taken
clinic
situat
old
boy
refer
pediatr
outpati
clinic
mild
fever
one
week
abdomin
pain
ultrasonographi
us
find
hepat
subcapsular
abscess
past
medic
histori
reveal
acut
append
two
year
ago
perihepat
abscess
one
year
ago
usguid
aspir
cultur
previou
liver
abscess
grew
entercoccu
avium
bacteroid
fragili
initi
laboratori
result
hospit
follow
wbc
neutrophil
lymphocyt
hemoglobin
gdl
platelet
crp
mgdl
total
bilirubin
mgdl
ast
ul
alt
ul
abdomin
ct
show
thick
wall
intern
septat
abscess
right
posterior
perihepat
space
without
hepat
involv
thought
associ
drop
appendicolith
hospit
day
usguid
aspir
percutan
abscess
drainag
done
bacteroid
fragili
cultur
pu
fusobacterium
nucleatum
subscepci
vincetii
also
identifi
via
bacteri
rdna
identif
patient
treat
iv
piperacillintazobactam
day
metronidazol
day
po
amoxicillinclavulan
remain
treatment
period
week
abdomin
us
find
discharg
show
collaps
abscess
caviti
cm
size
residu
fluid
collect
small
appendicolith
herebi
report
case
patient
two
episod
perihepat
abscess
may
associ
secondari
infect
retain
appendicolith
laparascop
appendectomi
case
woman
present
emerg
depart
fever
day
bilater
flank
pain
day
laboratori
result
abdominopelv
comput
tomographi
find
compat
apn
fig
without
prior
exposur
antibiot
ciprofloxacin
mg
intraven
twice
day
start
gramneg
bacilli
isol
initi
blood
urin
cultur
next
day
subsequ
blood
cultur
show
gnb
despit
ciprofloxacin
therapi
chang
antibiot
ertapenem
g
intraven
day
patient
clinic
cours
start
improv
esblproduc
e
coli
isol
identifi
three
consecut
blood
sampl
pfge
pattern
serotyp
sequenc
type
show
three
isol
deriv
ident
strain
tabl
mic
ciprofloxacin
broth
microdilut
method
increas
mgl
remain
within
suscept
rang
isol
resist
cephalosporin
except
ceftazidim
suscept
carbapenem
isol
produc
type
esbl
belong
clonal
group
failur
attribut
gyra
mutat
encod
within
quinolon
resistancedetermin
region
case
suggest
ciprofloxacin
use
cautious
treatment
seriou
infect
caus
esblproduc
e
coli
even
apn
due
ciprofloxacinsuscept
isol
six
month
earlier
diagnos
infect
treat
antivir
agent
tcell
count
mm
interferon
gamma
assay
posit
time
diagnosi
chest
xray
reveal
activ
lesion
therefor
treat
latent
tuberculosi
isoniazid
simultan
antiretrovir
therapi
howev
month
treatment
initi
pulmonari
tuberculosi
multipl
tubercul
lymph
node
supraclavicular
mediastin
area
detect
confirm
growth
mycobacterium
tuberculosi
cultur
sputum
lymph
node
biopsi
specimen
result
treat
isoniazid
rifabutin
ethambutol
pyrazinamid
month
treatment
visibl
mass
detect
right
supraclavicular
area
tcell
count
increas
preval
carbapenemresist
enterobacteriacea
cre
increas
treatment
option
cre
infect
limit
describ
case
sever
cre
infect
success
treat
fosfomycin
monotherapi
case
descript
singaporean
man
poorli
control
diabet
mellitu
admit
saudi
arabian
hospit
symptom
diarrhoea
complic
acut
renal
failur
requir
hemodialysi
support
flew
back
singapor
found
unrespons
flight
requir
admiss
intens
care
unit
spike
fever
th
day
admiss
blood
cultur
grew
cre
klebsiella
pneumonia
see
tabl
treat
combin
intraven
iv
meropenem
polymyxin
b
iv
tigecyclin
polymyxin
b
complet
week
antibiot
develop
fever
urin
blood
cultur
grew
klebsiella
pneumonia
isol
found
express
ndm
oxa
type
carbapenemas
continu
persist
fever
despit
combin
therapi
meropenem
polymyxin
b
blood
cultur
repeat
subsequ
resist
pattern
reveal
polymyxin
resist
neg
start
iv
cotrimoxazol
chang
iv
fosfomycin
g
view
worsen
renal
function
us
abdomen
show
left
kidney
complex
cystic
lesion
radiologicallyguid
drainag
abscess
done
cultur
grew
isol
success
treat
week
iv
fosfomycin
repeat
imag
end
therapi
show
resolut
discharg
well
discuss
cre
infect
hard
treat
limit
option
optim
treatment
clearli
defin
report
success
treatment
cre
renal
abscess
drainag
prolong
cours
iv
fosfomycin
dengu
viru
caus
agent
dengu
fever
transmit
aed
mosquito
progress
increas
geograph
distribut
sinc
past
sever
decad
especi
tropic
region
viru
infect
selflimit
patient
lifethreaten
ill
howev
viral
infect
still
lack
specif
treatment
vaccin
also
fulli
effect
prevent
depend
serotyp
viru
henc
secondari
infect
viru
import
must
special
consid
vaccin
endem
area
studi
investig
distribut
dengu
viru
southern
part
thailand
epidem
season
collect
serum
sampl
dengu
patient
perform
detect
nest
rtpcr
assess
serotyp
find
relationship
clinic
present
result
present
present
neg
result
rna
detect
serum
sampl
posit
dengu
viru
serotyp
follow
serotyp
respect
moreov
patient
dengu
shock
syndrom
found
cooper
dengu
serotyp
patient
confirm
secondari
infect
present
clinic
warn
sign
anticip
result
provid
inform
serotyp
circul
clinic
correl
dengu
viru
wider
start
point
discuss
consider
improv
precis
diagnosi
also
prevent
strategi
plan
background
acinetobact
baumannii
emerg
signific
opportunist
pathogen
involv
sever
nosocomi
infect
also
report
bacterium
associ
prematur
contract
chorioamnion
pregnanc
howev
report
associ
baumannii
caus
preterm
prematur
ruptur
membran
pprom
limit
studi
compar
incid
baumannii
pregnant
women
pprom
deliv
term
also
determin
subsequ
transmiss
bacterium
babi
materi
method
sampl
consist
high
vagin
swab
women
pprom
women
normal
pregnanc
babi
n
swab
collect
ear
axilla
within
six
hour
deliveri
swab
cultur
baumannii
acinetobact
select
media
chromagar
suspect
coloni
identifi
vitek
use
idgnb
card
result
baumannii
isol
eight
mother
pprom
eight
mother
normal
pregnanc
signific
differ
p
two
group
observ
amongst
pprom
mother
baumannii
colon
transmit
bacteria
babi
compar
normal
pregnanc
conclus
incid
baumannii
colon
pregnant
women
low
regardless
whether
pprom
suggest
colon
baumannii
pregnant
women
signific
role
lead
pprom
mother
pprom
high
possibl
transmit
bacterium
babi
background
haemaphysali
longicorni
act
major
vector
sft
viru
sftsv
tick
bite
import
risk
factor
human
infect
transmiss
sftsv
fatal
sft
patient
healthcar
worker
possibl
blood
respiratori
secret
nosocomi
area
herein
studi
possibl
indol
transmiss
sftsv
patient
asymptomat
famili
member
without
tick
bite
histori
method
introduc
surveil
famili
member
sft
patient
june
epidemiolog
investig
blood
sampl
collect
famili
member
within
two
week
index
patient
sft
diagnosi
realtim
polymeras
chain
reaction
molecular
analysi
use
diagnosi
tool
result
ten
sft
patient
confirm
studi
period
improv
sixteen
famili
member
sft
patient
investig
sampl
among
total
famili
cluster
two
famili
cluster
famili
member
posit
result
sftsv
symptom
sft
histori
contact
blood
bodi
fluid
index
patient
howev
stay
locat
within
prehospit
period
examin
prove
transmiss
mode
famili
member
sft
viru
identif
use
molecular
method
loos
stool
sinc
sftsv
neg
four
stool
specimen
sft
patient
conclus
knowledg
first
report
result
studi
highlight
potenti
secondari
infect
without
tick
bite
blood
contact
bloodi
secret
sftsv
endem
area
although
difficult
determin
scope
surveil
due
sft
transmiss
mode
remain
unclear
evid
possibl
droplet
transmiss
remain
limit
till
suggest
standard
droplet
precaut
requir
famili
member
direct
contact
febril
patient
epidem
period
hydatid
cyst
aliv
protoscolic
inhibit
growth
melanoma
tumor
anim
model
background
acut
pyelonephr
apn
lead
caus
communityacquir
bacteri
infect
materi
method
use
claim
databas
health
insur
review
assess
servic
hospit
patient
age
acut
tubulointerstiti
nephriti
andor
tubulointerstiti
nephriti
specifi
acut
chronic
code
primari
discharg
diagnosi
select
result
total
event
includ
geograph
analys
reveal
high
rel
risk
rr
apn
incid
area
gyeongsangnam
jeollanam
jeollabuk
provinc
popul
rr
p
gangwon
provinc
popul
rr
p
averag
popul
averag
medic
cost
treatment
apn
higher
metropolitan
area
seoul
rr
p
busan
rr
p
averag
hospit
day
longer
area
jeollanam
jeollabuk
chungcheongnam
provinc
day
rr
p
busan
surround
area
day
rr
p
averag
day
higher
amount
antibiot
prescrib
treatment
apn
daejeon
surround
area
ddd
rr
p
western
area
jeollabuk
provinc
ddd
rr
p
northern
area
gyeonggi
gangwon
provinc
ddd
rr
p
averag
ddd
conclus
region
differ
epidemiolog
apn
notic
antibiot
usag
treatment
apn
also
differ
region
korea
method
genotyp
perform
use
multilocu
sequenc
type
mlst
scheme
contig
queri
center
genom
epidemiolog
webbas
method
mlst
http
cgecbsdtudkservicesmlst
obtain
allel
profil
st
new
allel
allel
profil
submit
onlin
mlst
databas
curat
http
pubmlstorgcdiphtheria
genet
related
isol
infer
use
goeburst
algorithm
found
http
wwwphyloviznet
result
total
differ
st
identifi
isol
previous
describ
three
new
allel
also
identifi
dnak
new
allel
rpob
new
allel
locu
common
st
n
n
n
n
eburst
analysi
reveal
clonal
complex
cc
clone
singlelocu
variant
anoth
singleton
comparison
local
st
refer
st
avail
mlst
websit
show
none
local
isol
cluster
within
major
eburst
group
identifi
c
diphtheria
mlst
result
show
heterogen
among
toxigen
c
diphtheria
isol
malaysia
isol
also
uniqu
none
identifi
major
eburst
group
chronic
catherer
asymptomat
patient
unrel
reason
admiss
eg
hypertens
constip
clear
sourc
fever
immunocompet
haemodynam
stabl
patient
elderli
patient
nonspecif
symptomssign
eg
dizzi
breathless
site
infect
without
fever
eg
sacral
sore
leg
ulcer
object
aeromona
speci
increas
pathogen
bacteremia
especi
set
healthcareassoci
infect
investig
risk
factor
mortal
patient
aeromona
bacteremia
aeromona
bacteremia
januari
decemb
tertiari
care
center
seoul
korea
retrospect
review
analysi
perform
identifi
factor
associ
mortal
result
total
patient
aeromona
bacteremia
enrol
studi
common
pathogen
hydrophila
n
follow
cavia
n
veronii
biovar
sorbia
n
patient
male
median
age
year
common
sourc
aeromona
bacteremia
biliari
tract
follow
peritoneum
skin
soft
tissu
liver
abscess
primari
bacteremia
unknown
origin
overal
allcaus
mortal
rate
univari
analysi
skin
soft
tissu
infect
p
periton
p
healthcareassoci
infect
p
charlson
comorbid
score
p
sequenti
organ
failur
assess
sofa
score
p
significantli
relat
mortal
result
total
patient
pm
enrol
common
underli
diseas
diabet
mellitu
case
common
predispos
condit
trauma
case
total
organ
isol
patient
polymicrobi
infect
found
staphylococci
case
common
pathogen
follow
streptococci
case
enter
gramneg
organ
identifi
patient
methicillinresist
staphylococcu
aureu
mrsa
identifi
patient
communityacquir
case
vs
healthcareassoci
case
p
inhospit
mortal
rate
old
age
intens
care
unit
admiss
septic
shock
significantli
associ
inhospit
mortal
conclus
underli
condit
sever
associ
inhospit
mortal
mrsa
seem
uncommon
caus
organ
pm
korea
enrol
clinic
symptom
confirm
gene
typespecif
antigen
amplifi
nest
pcr
nucleotid
sequenc
pcr
product
determin
nucleotid
sequenc
obtain
scrub
typhu
patient
retriev
genbank
databas
analyz
phylogenet
result
pcr
result
pcrposit
sampl
obtain
sampl
show
boryong
genotyp
dna
sequenc
analys
thirteen
sampl
show
taguchi
genotyp
korean
type
jecheon
yeojoo
pajoo
relat
strain
also
identifi
japanes
type
karp
kawasaki
ikeda
nishino
also
found
case
found
group
age
conclus
result
preval
type
tsutsugamushi
boryong
korea
howev
unusu
type
origin
korean
japanes
strain
also
found
consecut
broadrang
nation
survey
preval
need
control
prevent
scrub
typhu
endem
region
korea
background
group
streptococcu
ga
common
pathogen
pediatr
patient
often
caus
acut
pharyngotonsil
skin
soft
tissu
infect
addit
bacteremia
also
occur
method
singlecent
retrospect
studi
januari
decemb
pediatr
patient
year
old
ga
bacteremia
studi
result
among
patient
posit
ga
cultur
result
patient
ga
bacteremia
eleven
patient
male
median
age
year
rang
year
fourteen
patient
chronic
underli
diseas
five
immunocompromis
patient
eight
patient
lymphat
vascular
malform
seven
inflammatori
sign
lesion
three
patient
acut
lymphoblast
leukemia
present
fever
without
sore
throat
sign
skin
soft
tissu
infect
two
patient
underli
chronic
kidney
diseas
three
patient
develop
pneumonia
two
receiv
ventil
care
two
patient
previous
healthi
children
one
patient
chronic
bedridden
condit
microcephali
homeventil
care
mortal
ga
isol
sensit
penicillin
fifteen
sensit
erythromycin
clindamycin
conclus
studi
show
variou
clinic
present
invas
ga
infect
although
uncommon
ga
consid
potenti
pathogen
caus
bacteremia
seriou
clinic
cours
background
porcin
respiratori
diseas
complex
prdc
greatli
affect
health
product
pig
caus
signific
econom
loss
swine
farm
diseas
commonli
associ
bacteri
pathogen
identif
bacteri
pathogen
get
topic
great
interest
studi
pcr
cultur
method
compar
detect
five
bacteri
pathogen
mostli
associ
prdc
worldwid
pasteurella
multocida
pm
mycoplasma
hyopneumonia
mh
streptococcu
sui
ss
actinobacillu
pleuropneumonia
app
haemophilu
parasui
hp
lung
tissu
patholog
lesion
case
cultur
method
matrixassist
laser
desorpt
ionizationtim
flight
malditof
use
identifi
bacteri
speci
follow
coloni
isol
bacteri
cultur
method
total
lung
sampl
patholog
lesion
obtain
two
slaughterhous
decemb
juli
tissu
homogen
ml
pb
use
stomach
genom
dna
extract
ml
homogen
solut
spin
pcr
perform
specif
set
primer
target
pathogen
use
extract
dna
sampl
homogen
sampl
also
use
isol
bacteria
streak
onto
sheep
blood
agar
follow
overnight
cultur
suspect
coloni
pm
mh
ss
app
hp
subject
malditof
assay
identifi
bacteri
speci
result
tissu
sampl
process
pcr
detect
five
pathogen
highest
detect
rate
mh
n
follow
ss
hp
app
pm
respect
contrast
cultur
method
detect
ss
pm
app
none
sampl
posit
mh
hp
cultur
method
cultur
posit
sampl
pathogen
neg
pcr
except
sampl
ss
posit
combin
result
pcr
cultur
method
overal
preval
prdc
associ
bacteri
pathogen
patholog
lung
tissu
highest
mh
follow
pm
ss
app
hp
respect
conclus
prdc
polymicrobi
diseas
caus
infect
variou
combin
primari
secondari
bacteri
pathogen
import
investig
relev
signific
bacteri
pathogen
prdc
control
diseas
mh
preval
bacteri
pathogen
studi
indic
mh
signific
bacteri
pathogen
prdc
korea
pm
ss
second
third
preval
bacteri
pathogen
app
hp
rare
associ
prdc
two
detect
method
use
current
studi
show
clearli
differ
sensit
pathogen
mh
hp
detect
pcr
pm
ss
identifi
cultur
method
follow
malditof
assay
moreov
pcr
cultur
method
detect
differ
portion
posit
sampl
respect
studi
therefor
use
combin
method
pcr
cultur
might
use
increas
sensit
detect
prdc
associ
bacteri
pathogen
oblig
intracellular
bacterium
anaplasma
phagocytophilum
caus
human
granulocyt
anaplasmosi
hga
bacterium
tickborn
pathogen
mainli
transmit
ixod
tick
infect
domest
mammal
human
molecular
character
protein
phagocytophilum
may
determin
bacterium
capabl
invad
host
also
whether
gener
antigen
variat
purpos
escap
host
immun
respons
result
variou
patholog
injuri
seriou
clinic
outcom
korea
hga
patient
usual
present
acut
fever
muscl
pain
headach
studi
confirm
seroposit
andor
seroconvers
phagocytophilum
infect
use
indirect
immunofluoresc
antibodi
assay
ifa
patient
acut
fever
also
amplifi
clone
sequenc
part
phagocytophilum
gene
detect
hga
patient
compar
sequenc
avail
genbank
compar
data
show
sequenc
obtain
korean
patient
high
similar
one
anoth
wherea
significantli
differ
sequenc
detect
human
usa
china
result
provid
clue
understand
distinct
genet
character
phagocytophilum
origin
korean
patient
might
relev
clinic
outcom
might
suggest
help
inform
studi
need
understand
mechan
escap
host
immun
respons
molecular
character
protein
result
pathogen
identifi
blood
liver
aspir
andor
vitreou
humor
sampl
klebsiella
pneumonia
frequent
organ
candida
next
common
common
combin
infect
liver
abscess
renal
abscess
acut
pyelonephr
two
die
due
fulmin
infect
final
ocular
outcom
nlp
lp
hm
fc
k
pneumonia
poor
prognosi
factor
ocular
outcom
nlp
lp
vs
hm
cf
better
univari
analysi
p
factor
reach
statist
differ
tree
decis
analysi
also
reveal
k
pneumonia
node
divid
outcom
p
conclus
k
pneumonia
frequent
pathogen
ee
addit
seem
poor
prognost
factor
ocular
outcom
consid
rapid
progress
poor
prognosi
ee
earli
diagnosi
immedi
manag
vital
especi
k
pneumonia
identifi
suspect
keyword
endogen
endophthalm
klebsiella
pneumonia
ocular
outcom
nonhacek
gram
neg
bacillu
endocard
develop
countri
dr
r
madhumitha
dr
v
ramasubramanian
dr
p
senthur
nambi
dr
r
gopalakrishnan
dr
sathyamurthi
background
predomin
caus
pathogen
bacteri
endocard
nearli
case
continu
gram
posit
bacteria
emerg
newer
risk
factor
prolong
hospit
devic
insert
escal
antimicrobi
resist
chang
epidemiolog
diseas
develop
world
incid
gramneg
endocard
develop
world
rang
mostli
hacek
haemophilu
speci
actinobacillu
actinomycetemcomitan
cardiobacterium
homini
eikenella
corroden
kingella
speci
organ
object
studi
conduct
tertiari
care
hospit
south
india
review
chang
epidemiolog
risk
factor
nonhacek
gramneg
bacillu
endocard
method
patient
record
januari
year
infect
endocard
ie
per
modifi
duke
criteria
analys
retrospect
result
total
case
definit
ie
analys
nativ
vale
prosthet
valv
patient
posit
cultur
gram
posit
pathogen
streptococcu
sp
commonest
bacteria
isol
gram
neg
bacteria
seen
nativ
valv
prosthet
valv
escherichia
coli
patient
commonest
pathogen
extend
spectrum
betalactamas
produc
major
patient
urinari
tract
common
portal
entri
nosocomi
infect
particularli
dialysi
relat
central
venou
cathet
infect
septic
embol
complic
seen
conclus
non
hacek
gramneg
bacilli
rel
rare
caus
endocard
epidemiolog
risk
factor
develop
gramneg
endocard
includ
multidrug
resist
pathogen
emerg
health
care
contact
primari
risk
factor
acquisit
nonhacek
endocard
pacif
region
aim
present
studi
evalu
microbiolog
differ
urinari
tract
infect
hypervirul
phenotyp
compar
liver
abscess
origin
method
studi
perform
k
pneumonia
isol
patient
commun
acquir
urinari
tract
infect
n
liver
abscess
n
diagnos
keimyung
univers
dongsan
medic
center
januari
juli
hypermucovisc
phenotyp
confirm
string
test
capsular
serotyp
rmpa
maga
kfu
all
iuta
identifi
use
specif
primer
polymeras
chain
reaction
compar
antimicrobi
suscept
virul
factor
accord
origin
result
hypermucovisc
phenotyp
serotyp
less
urinari
tract
infect
liver
abscess
among
virul
factor
rmpa
maga
all
iuta
less
frequent
observ
urinari
tract
infect
subgroup
analysi
hypervirul
k
pneumonia
serotyp
rmpa
maga
iuta
less
observ
urinari
tract
infect
identifi
score
assign
follow
point
temperatur
neutrophil
l
neutrophil
ls
crp
mgl
urea
mmoll
point
neutrophilmonocyt
nm
ratio
ls
crp
mgl
pct
ngml
point
nm
ratio
ls
sum
score
sensit
specif
neg
predict
valu
posit
predict
valu
respect
p
valu
goodnessoffit
test
model
area
roc
curv
optim
conclus
predict
score
bacteremia
could
use
stratifi
risk
bacteremia
safe
reduc
blood
cultur
take
admiss
background
rickettsia
orientia
speci
gram
neg
strictli
intracellular
bacilli
multipli
within
cytosol
endotheli
cell
scrub
typhu
miteborn
diseas
caus
orientia
tsutsugamushi
infect
occur
frequent
autumn
korea
incid
diseas
show
tendenc
increas
climat
chang
outdoor
activ
rickettsia
typhi
typhu
group
rickettsia
etiolog
agent
murin
endem
typhu
r
typhi
transmit
human
primarili
rat
flea
xenopsylla
cheopi
although
lice
mite
also
potenti
vector
korea
case
scrub
typhu
report
sinc
first
case
report
howev
murin
typhu
report
case
surveil
studi
obtain
basic
data
scrub
typhu
murin
typhu
prevent
control
highrisk
popul
materi
method
studi
perform
nation
park
worker
consid
highrisk
popul
rickettsia
diseas
elig
particip
forestri
worker
sera
collect
antibodi
specif
tsutsugamushi
r
typhi
titrat
use
indirect
immunofluoresc
antibodi
assay
ifa
igg
igm
consid
singl
cutoff
titer
seropreval
result
seropreval
rate
indic
higher
titer
singl
cutoff
seroreact
rate
indic
titrat
singl
cutoff
scrub
typhu
show
respect
murin
typhu
show
respect
moreov
seropreval
scrub
typhu
murin
typhu
conclus
first
serolog
studi
murin
typhu
among
forestri
worker
consid
highrisk
popul
high
exposur
r
typhi
amongst
forestri
worker
suggest
fleaborn
spot
fever
import
caus
undifferenti
fever
condit
may
adequ
recogn
korea
therefor
continu
surveil
need
understand
statu
improv
control
prevent
diseas
highrisk
popul
explor
potenti
effect
gender
clinic
outcom
staphylococcu
aureu
bacteremia
sab
hiv
preval
malaysia
remain
high
especi
among
high
risk
popul
person
inject
drug
pwid
femal
sex
worker
fsw
transgend
tg
men
sex
men
msm
hiv
infect
asymptomat
signific
period
time
lead
delay
diagnosi
especi
among
low
risk
popul
asymptomat
peopl
capabl
transmit
infet
asymptomat
low
risk
popul
vital
play
role
curb
upris
hiv
infect
studi
aim
provid
preliminari
data
hiv
preval
among
perceiv
low
risk
patient
specialist
center
malaysia
retrospect
studi
done
data
patient
screen
hiv
antibodyantigen
chemiluminesc
imunoassay
clia
year
examin
patient
undergo
hiv
screen
routin
either
cardiac
procedur
part
antenat
checkup
high
risk
behaviour
record
reactiv
clia
confirm
particl
agglutin
test
new
case
detect
screne
nineti
six
percent
male
major
age
rang
year
studi
show
screen
detect
small
signific
percentag
new
hiv
case
among
perceiv
low
risk
patient
provid
oppoturn
earli
diagnosi
manag
vari
rate
immun
recoveri
hiv
patient
haart
age
categori
implic
n
background
age
known
neg
predictor
immun
recoveri
follow
highli
activ
antiretrovir
therapi
haart
nonlinear
associ
wellcharacteris
method
collect
longitudin
clinic
data
hiv
specialist
clinic
hong
kong
use
ratio
examin
immun
recoveri
chines
patient
haart
year
three
age
categori
haart
initi
defin
young
adult
middleag
elderli
late
haart
initi
defin
prehaart
aid
diagnosi
gener
estim
equat
use
analys
associ
age
categori
tempor
chang
clinic
immun
outcom
marker
month
result
total
patient
male
analys
haart
initi
young
adult
middleag
elderli
baselin
median
ratio
iqr
iqr
iqr
respect
middleag
like
late
haart
initi
young
adult
similar
elderli
perform
recoveri
worsen
along
age
categori
best
young
adult
revers
declin
largest
drop
among
elderli
smallest
young
adult
ushap
relationship
age
categori
rate
ratio
recoveri
note
middleag
slowest
recoveri
conclus
recoveri
middleag
might
occur
faster
elderli
recoveri
slower
immun
recoveri
middleag
may
improv
haart
could
start
earli
shorten
interv
diagnosi
treatment
initi
patient
diagnosi
hiv
infect
aid
review
univers
hospit
locat
seoul
republ
korea
acut
hiv
infect
defin
patient
initi
screen
antibodi
elisa
neg
subsequ
seroconvers
within
month
clinic
symptom
result
patient
diagnos
acut
hiv
infect
male
median
age
time
diagnosi
median
valu
log
hiv
viral
load
rna
rtpct
time
diagnosi
median
count
patient
acut
hiv
infect
commonli
fever
mean
durat
day
follow
gastrointestin
symptom
nausea
vomit
diarrhea
tonsillar
enlarg
leukopenia
wbc
count
thrombocytopenia
platelet
count
present
method
review
retrospect
medic
record
hivinfect
patient
treat
haart
singl
tertiari
hospit
sinc
januari
hyperlactatemia
defin
serum
lactat
mmoll
factor
analyz
comparison
group
show
increment
serum
la
level
group
control
group
show
normal
decreas
serum
la
level
group
result
among
case
includ
case
group
show
increas
la
haart
rang
mmoll
differ
distribut
haart
regimen
two
group
p
accord
nrti
use
haart
group
group
p
differ
underli
diseas
coinfect
metabol
diseas
psychiatr
diseas
two
group
howev
initi
serum
albumin
gdl
vs
gdl
group
vs
group
p
hemoglobin
level
gdl
vs
gdl
group
vs
group
p
show
statist
signific
differ
increment
cell
count
background
advanc
human
immunodefici
viru
hiv
infect
copiou
opportunist
infect
hiv
relat
cancer
rel
risk
much
higher
compar
gener
popul
diffus
larg
bcell
lymphoma
dlbcl
one
diseas
involv
lymph
node
extranod
site
lung
involv
unusu
case
report
report
case
pulmonari
dlbcl
combin
multipl
infect
hiv
posit
man
present
bizarr
cystic
radiolog
find
whose
main
symptom
gener
weak
kg
weight
loss
two
month
chronic
cough
diagnos
advanc
hiv
infect
count
chest
radiolog
find
identifi
multifoc
septat
cystic
lesion
thin
wall
upper
lung
adjac
normal
parenchym
lesion
like
vari
state
cystic
necrot
chang
chest
radiolog
find
atyp
clinic
sign
unclear
video
assist
thoracostomi
vat
biopsi
conduct
sake
prompt
diagnosi
histopatholog
find
demonstr
dlbcl
posit
ebv
infect
pneumocysti
jirovercii
pcp
infect
mycobacterium
avium
also
isol
afb
cultur
test
although
chemotherapi
could
perform
poor
gener
condit
antiretrovir
therapi
start
success
week
treatment
antimycobacteri
antibiot
pcp
gener
condit
becam
better
infecti
diseas
control
conclus
case
pulmonari
dlbcl
multipl
infect
show
atyp
chest
radiolog
pattern
advanc
hiv
patient
earli
vat
biopsi
also
help
earli
diagnosi
background
may
world
health
assembl
adopt
global
action
plan
antimicrobi
resist
amr
reflect
global
consensu
amr
threaten
human
health
accordingli
develop
global
antimicrobi
resist
surveil
system
glass
promot
standard
amr
surveil
global
goal
glass
enabl
standard
compar
valid
data
amr
collect
analyz
share
countri
sinc
may
korea
center
diseas
control
prevent
establish
amr
surveil
system
gener
hospit
six
larg
citi
provinc
korea
compat
glass
name
korglass
defin
specimen
blood
urin
fece
urethr
cervic
swab
prioriti
pathogen
isol
antimicrobi
suscept
prioriti
pathogen
determin
method
total
pathogen
test
includ
escherichia
coli
klebsiella
pneumonia
acinetobact
spp
pseudomona
aeruginosa
staphylococcu
aureu
enterococcu
faecali
enterococcu
faecium
streptococcu
pneunonia
salmonella
spp
shigella
spp
neisseria
gonorrhoea
glassrecommend
pathogen
pathogen
design
statutori
infecti
diseas
antibiot
suscept
test
perform
disk
diffus
etest
broth
microdilut
agar
dilut
method
use
accord
speci
antibiot
result
confirm
accord
clinic
laboratori
standard
institut
clsi
european
committe
antimicrobi
suscept
test
eucast
result
total
strain
collect
may
april
year
shigella
spp
n
gonorrhoea
collect
resist
rate
e
coli
k
pneumonia
cefotaxim
respect
p
aeruginosa
baumannii
show
resist
carbapenem
antibiot
respect
rate
mrsa
aureu
isol
form
blood
enterococci
isol
blood
resist
rate
ampicillin
e
faecali
e
faecium
respect
aureu
e
coli
baumannii
e
faecium
multidrug
resist
conclus
korglass
may
produc
meaning
data
global
level
enabl
analysi
occurr
trend
amr
establish
prevent
control
programm
amr
background
object
leishmaniasi
major
health
problem
global
affect
million
peopl
especi
develop
countri
scienc
immunoprophylaxi
vaccin
access
leishmania
infect
commerci
drug
unsatisfactori
therefor
object
present
survey
state
antileishmani
activ
two
herbal
medicin
satureja
khuzestanica
leaf
heracleum
persicum
fruit
extract
evalu
leishmania
major
leishmania
infantum
use
colorimetr
mtt
bromid
assay
compar
glucantim
refer
materi
method
leav
extract
select
plant
obtain
macer
vitro
assay
carri
leishmania
major
leishmania
infantum
use
colorimetr
mtt
assay
comparison
glucantim
concentrationrespons
curv
test
extract
glucantim
solut
design
ic
valu
locat
result
antileishmina
effect
satureja
khuzestanica
heracleum
persicum
l
major
l
infantum
promastigot
reveal
inhibitori
concentr
valu
mg
ml
satureja
khuzestanica
mg
ml
heracleum
persicum
comparison
standard
drug
glucantim
valu
mg
ml
l
major
mg
ml
l
infantum
promastigot
hour
incub
respect
conclus
result
reveal
compound
satureja
khuzestanica
heracleum
persicum
antileishmania
properti
necessari
survey
effect
extract
leishmania
genu
anim
model
futur
keyword
antileishmani
activ
leishmania
major
leishmania
infantum
glucantim
promastigot
mtt
assay
identif
pathogen
bacteria
cosmet
test
public
shop
north
jakarta
indonesia
aisyah
g
cosmet
test
one
essenti
activ
costum
decid
purchas
beauti
product
howev
cosmet
sampl
use
mani
peopl
predominantli
direct
contact
open
air
risk
contamin
wide
rang
microorgan
studi
aim
detect
presenc
pathogen
bacteria
liquid
solid
lipstick
public
shop
north
jakarta
indonesia
six
sampl
lipstick
type
randomli
select
cultur
select
nonselect
medium
biochem
test
conduct
coloni
differ
morpholog
sampl
test
shigella
found
liquid
solid
form
lipstick
respect
hand
e
coli
found
liquid
lipstick
contamin
might
come
user
amen
person
hygien
practic
constitut
potenti
hazard
gi
tract
tester
accident
ingest
studi
regard
abil
pathogen
bacteria
exist
cosmet
sampl
transmit
diseas
among
tester
need
implement
intersectori
one
health
antimicrobi
resist
amr
contain
programm
malaysia
background
incid
amr
increas
around
world
affect
level
societi
thu
make
amr
global
health
threat
amr
complex
epidemiolog
problem
due
fact
variou
causal
factor
intertwin
method
ministri
health
moh
malaysia
taken
step
combat
amr
initi
measur
within
moh
well
intersector
one
health
approach
moh
steer
initi
one
health
approach
combat
amr
involv
variou
sector
human
anim
health
start
draft
malaysia
action
plan
amr
focus
four
prioriti
area
consist
educ
awar
surveil
research
infect
prevent
control
appropri
use
antimicrobi
time
nation
amr
committe
narc
establish
coordin
bodi
govern
contain
activ
implement
narc
framework
four
technic
work
group
respons
implement
plan
strategi
result
malaysia
success
establish
intersectori
one
health
amr
framework
govern
contain
activ
set
malaysia
action
plan
amr
steer
committe
support
four
technic
work
group
respons
execut
strategi
respect
prioriti
area
one
main
outcom
implement
integr
one
health
amr
surveil
conclus
amr
becom
increasingli
urgent
challeng
public
health
threat
malaysia
intersectori
collabor
need
share
evid
trend
amr
use
antimicrobi
relat
sector
awar
educ
infect
prevent
control
antimicrobi
stewardship
programm
drive
forc
contain
amr
success
measur
achiev
one
health
approach
background
cancer
main
caus
death
develop
countri
scientif
evid
indic
parasit
infect
induc
antitumor
activ
certain
type
cancer
hydatid
cyst
larval
stage
echinococcu
granulosu
caus
hydatidosi
human
livestock
studi
effect
aliv
hydatid
cyst
protoscolic
melanoma
tumor
mice
investig
materi
method
investig
two
group
mice
challeng
melanoma
cell
week
one
group
inject
aliv
protoscolic
case
group
next
group
left
intact
control
group
tumor
size
case
control
group
measur
data
analyz
use
spss
softwar
oneway
anova
test
result
result
demonstr
aliv
protoscolic
hydatid
cyst
inhibit
melanoma
tumor
growth
case
group
differ
mean
size
tumor
case
control
group
statist
signific
conclus
result
studi
show
inject
aliv
protoscolic
hydatid
cyst
signific
effect
melanoma
tumor
growth
background
deepseawat
dsw
contain
sever
miner
benefici
human
bodi
effect
dsw
known
improv
specif
immun
function
benefici
effect
dsw
suggest
could
use
develop
new
health
function
food
purpos
studi
evalu
microbiolog
food
safeti
meat
product
process
dsw
materi
method
concentr
dsw
cdsw
contain
salt
use
bacteri
kill
activ
measur
e
coli
salmonella
typhimurium
enter
respect
incub
bacteria
cdsw
salin
control
measur
viabl
bacteria
h
two
differ
pork
sausag
produc
use
tradit
cure
solut
cdsw
bacteri
contamin
sausag
measur
differ
time
point
result
bacteri
surviv
cdsw
control
salin
assess
measur
coloni
form
unit
cfu
differ
time
point
surviv
rate
three
test
bacteria
rapidli
decreas
cdsw
control
solut
bacteri
contamin
studi
bacteria
detect
either
tradit
cdsw
sausag
day
conclus
dsw
show
degre
bacteri
kill
activ
pork
sausag
made
dsw
show
bacteri
contamin
kept
steril
condit
day
post
product
contamin
studi
progress
extend
time
point
measur
result
indic
dsw
could
use
altern
cure
solut
process
meat
product
background
sitafloxacin
exhibit
broad
antibacteri
spectrum
excel
antimicrobi
activ
common
bacteri
pathogen
caus
differ
infect
sitafloxacin
also
exhibit
excel
clinic
efficaci
patient
fail
respond
antibacteri
therapi
howev
sitafloxacin
avail
vietnam
yet
local
inform
invitro
spectrum
antibiot
common
bacteri
pathogen
isol
vietnam
necessari
help
doctor
choic
exist
situat
antibiot
resist
viet
nam
main
aim
studi
use
microdilut
method
determin
ratio
sensit
mic
sitafloxacin
common
use
antibiot
common
bacteri
pathogen
isol
clinic
sampl
collect
patient
acut
lower
respiratori
tract
infect
acut
urinari
tract
infect
object
method
object
studi
bacteri
pathogen
isol
sputum
includ
pneumonia
h
influenza
catarrhali
aureu
k
pneumonia
p
aeruginosa
baumannii
urin
includ
e
coli
p
mirabili
e
faecali
e
faecium
baumannii
p
aeruginosa
k
pneumonia
pathogen
least
isol
collect
isol
collect
differ
hospit
ho
chi
minh
citi
ha
noi
one
year
determin
mic
antibiot
bacteri
pathogen
carri
broth
microdilut
method
follow
clsi
carryout
mic
plate
well
contain
dri
antibiot
serial
concentr
custom
fabric
suppli
eiken
chemic
co
ltd
dri
plate
eiken
tokyo
japan
use
result
discuss
isol
collect
hospit
ho
chi
minh
hospit
ha
noi
includ
isol
lower
respiratori
tract
infect
isol
urinari
tract
receiv
result
demonstr
h
influenza
sensit
sitafloxacin
equival
amoxicillinclavulan
acid
cefotaxim
ceftriaxon
imipenem
howev
sitafloxacin
gave
low
mic
ml
lowest
versu
antibiot
pneumonia
isol
sensit
sitafloxacin
mic
lowest
versu
antibiot
sitafloxacin
among
antibiot
high
sensit
ratio
catarrhali
gave
lowest
mic
cocci
gram
like
mrsa
mssa
e
faecali
e
faecium
sitafloxacin
gave
high
sensit
ratio
equival
vancomycin
mssa
vancomycin
mrsa
e
faecali
e
faecium
howev
case
higher
sensit
ratio
antibiot
baumannii
sitafloxacin
gave
sensit
ratio
antibiot
sensit
ratio
p
aeruginosa
sitafloxacin
gave
result
sensit
ratio
highest
compar
antibiot
esbl
e
coli
sitafloxacin
gave
sensit
ratio
meropenem
antibiot
esbl
k
pneumonia
although
sensit
ratio
could
reach
howev
ratio
lower
meropenem
higher
antibiot
gave
sensit
ratio
e
coli
k
pneumonia
esbl
well
proteu
spp
sitafloxacin
among
antibiot
highest
sensit
ratio
conclus
first
trial
findout
invitro
activ
sitafloxacin
differ
bacteri
pathogen
isol
clinic
sampl
viet
nam
result
collect
studi
demonstr
sitafloxacin
exhibit
excel
invitro
antibacteri
activ
gramposit
gramneg
bacteria
mostli
encount
clinic
field
infect
result
confirm
sitafloxacin
consid
one
power
antibiot
doctor
use
treat
variou
infect
caus
antibiot
resist
bacteri
pathogen
retrospect
studi
aim
evalu
level
coagul
factor
presenc
dissemin
intravascular
coagul
dic
patient
scrub
typhu
includ
patient
confirm
scrub
typhu
chosun
univers
hospit
septemb
decemb
dic
score
evalu
patient
healthi
control
median
concentr
fibrinogen
ddimer
fibrin
fibrinogen
degrad
product
fdp
compar
patient
healthi
control
p
test
patient
scrub
typhu
longer
prothrombin
time
lower
platelet
count
control
major
bleed
observ
patient
scrub
typhu
fiftyon
patient
present
sever
complic
scrub
typhu
overt
dic
thrombocytopenia
plateletsmm
observ
frequent
patient
bleed
sever
ill
furthermor
median
platelet
count
low
group
approxim
n
n
patient
scrub
typhu
overt
dic
defin
intern
societi
thrombosi
hemostasi
dic
score
dicscor
templat
fibrinogencreact
proteinratio
respect
three
patient
bleed
overt
dic
defin
respect
seven
patient
sever
ill
overt
dic
defin
respect
conclus
activ
coagul
system
import
featur
scrub
typhu
correl
sever
diseas
includ
bleed
first
studi
report
relationship
dic
scrub
typhu
background
qualiti
manuscript
edit
necessari
public
intern
medic
journal
especi
nonn
englishspeak
extern
edit
servic
ee
popular
author
often
unsatisfi
cost
timeli
qualiti
servic
result
institut
launch
inhous
edit
servic
ihe
work
close
author
person
meet
need
method
design
survey
monitor
author
satisfact
compar
preliminari
data
one
survey
item
correspond
result
ee
use
institut
past
year
author
rate
ihe
use
likert
scale
answer
follow
question
request
finish
time
manner
editor
fulli
comprehend
manuscript
correct
correspond
intent
mani
addit
correct
make
consult
help
would
rate
overal
satisfact
servic
first
time
use
team
servic
first
time
use
edit
servic
would
rate
rel
satisfactori
rate
compar
servic
would
use
servic
would
recommend
servic
peer
result
overal
satisfactori
rate
ihe
question
ihe
score
significantli
higher
correspond
result
anoth
survey
evalu
ee
mean
rang
mean
p
conclus
author
highli
satisfi
newlyestablish
ihe
deem
editor
fuller
comprehens
manuscript
ee
editor
background
singapor
current
two
rout
pursu
career
medic
technologist
mt
via
bachelor
degre
biomed
scienc
equival
two
local
univers
sciencerel
diplomaspeci
diploma
five
polytechn
academ
train
cover
core
disciplin
laboratori
medicin
eg
haematolog
clinic
chemistri
medic
microbiolog
transfus
medicin
cytohistopatholog
student
pass
theoret
examin
complet
practic
placement
work
laboratori
deem
compet
mt
report
summaris
academ
train
microbiolog
mt
method
typic
microbiolog
disciplin
involv
mani
manual
process
cultur
plate
recognis
identifi
potenti
pathogen
suscept
antibiot
today
bench
microbiolog
mt
need
acquir
skill
knowledg
autom
walkaway
sampl
plate
autom
identif
suscept
test
system
learn
newer
mass
spectrometri
techniqu
allow
bacteria
identif
reduct
turnaround
time
tat
minut
acquir
molecular
techniqu
improv
tat
sensit
specif
develop
medic
informat
process
algorithm
manag
process
control
decis
make
scientif
analysi
expert
report
antibiot
antibiot
stewardship
support
accur
reflex
test
emphasi
qualiti
manag
qualiti
control
plan
essenti
continu
skill
knowledg
improv
maintain
compet
currenc
microbiolog
crucial
result
current
academ
program
need
provid
necessari
profession
develop
relev
dynam
chang
today
laboratori
servic
longdeb
whether
multipl
sputum
specimen
three
exact
absolut
requir
pulmonari
tuberculosi
tb
diagnosi
studi
high
tb
burden
countri
shown
diagnos
effect
use
two
specimen
howev
research
low
tb
burden
countri
present
contradictori
find
studi
set
evalu
optimum
number
sputa
requir
diagnos
tb
acid
fast
bacilli
afb
smear
microscopi
moder
tb
burden
countri
malaysia
retrospect
review
acidfast
bacillu
afb
smear
kinyoun
stain
microscopi
result
three
consecut
sputum
specimen
cultureconfirm
tb
patient
cohort
patient
includ
inpati
outpati
present
hiv
patient
foreign
origin
high
low
tb
burden
countri
exclud
data
afb
posit
patient
eventu
analys
twentysix
success
diagnos
base
first
sputum
twentynin
patient
afb
posit
base
either
first
sputum
second
sputum
meant
collect
two
consecut
specimen
improv
afb
detect
final
two
patient
requir
third
sputum
examin
eventu
clinch
diagnosi
overal
third
sputum
appear
signific
addit
diagnost
valu
afb
detect
microscopi
conclud
examin
two
sputum
specimen
suffici
effect
diagnosi
moder
tb
burden
countri
also
lessen
financi
implic
patient
healthcar
system
latter
decreas
laboratori
workload
shorten
period
mandatori
tb
isol
smearneg
patient
background
rapid
differenti
mycobacterium
tuberculosi
complex
mtbc
nontubercul
mycobacteria
ntm
import
earli
effect
treatment
mtbc
specif
antigen
secret
bacteri
growth
shown
excel
target
differenti
mtbc
ntm
studi
investig
frequenc
ag
neg
pcr
posit
mtbc
strain
isol
clinic
specimen
korea
method
januari
decemb
afb
cultur
perform
clinic
specimen
use
ogawa
medium
bactec
mgit
system
bd
diagnost
usa
afb
stain
ag
assay
perform
cultur
strain
ag
neg
strain
pcr
perform
first
strain
multipl
isol
patient
includ
studi
result
afb
cultur
posit
specimen
posit
strain
neg
strain
pcr
posit
strain
case
report
mtbc
case
neg
strain
among
case
report
mix
growth
mtbc
ntm
case
neg
conclus
preval
ag
neg
pcr
posit
mtbc
strain
isol
clinic
sampl
last
year
korea
mtbc
strain
mix
growth
ntm
neg
fals
neg
may
attribut
lower
concentr
protein
could
also
explain
delet
mutat
gene
studi
gene
pcr
sequenc
perform
neg
assay
exclud
diagnosi
tuberculosi
neg
isol
convent
molecular
test
requir
confirm
presenc
mtbc
neonat
splenic
hepat
tuberculosi
case
report
review
literatur
z
yang
beij
children
hospit
china
prc
background
congenit
tuberculosi
rare
even
tuberculosi
tb
endem
girl
present
histori
fever
origin
infant
abdomin
ultrasound
show
multipl
node
liver
spleen
antibiot
therapi
includ
use
linezolid
venou
week
node
decreas
disminish
linezolid
chang
orallyadministr
sequenti
therapi
fever
recurr
neurolog
symptom
appear
discharg
mother
asymptomat
chest
radiograph
nt
show
evid
tb
infect
like
bilater
miliari
nodul
ppd
test
neg
final
diagnos
tb
infect
posit
tspot
congenit
tb
strongli
suspect
symptom
sign
matern
tb
histori
confirm
tspot
time
administr
standard
antitb
therapi
combin
linezolid
result
good
outcom
patient
case
highlight
import
differenti
diagnos
splenic
hepat
tuberculosi
linezolid
neonat
tb
may
facilit
treatment
prognosi
singl
use
case
present
report
complic
case
congenit
tb
girl
present
depart
pediatr
emerg
room
beij
children
hospit
bch
linkou
fever
day
durat
second
child
woman
born
local
hospit
caesarean
section
week
gestat
weigh
g
temperatur
apgar
score
min
respect
admiss
weigh
g
temperatur
puls
beatsminut
blood
pressur
mm
hg
respiratori
rate
breathsminut
chest
wall
retract
coars
breath
sound
present
remaind
physic
examin
normal
cyanosi
lymphadenopathi
hepatosplenomegali
previous
infant
mother
healthi
histori
tb
contact
conclus
case
aim
emphas
import
includ
congenit
tuberculosi
differenti
diagnosi
young
infant
admit
fever
reason
abdomin
ultrasound
show
dissemin
hepat
splenic
nodal
linezolid
use
treatment
congenit
tuberculosi
singl
use
cours
controversi
make
earli
recognit
crucial
lifesav
result
tb
patient
seen
faculti
medicin
uitm
januari
decemb
retrospect
analyz
cultur
sensit
test
result
perform
use
bd
bactec
mgit
sire
system
includ
cultur
result
without
comprehens
suscept
pattern
exclud
first
line
drug
includ
data
streptomycin
str
isoniazid
inh
rifampicin
rif
ethambutol
eth
total
sixtyseven
posit
result
mtb
cultur
sensit
obtain
sixtytwo
isol
sensit
four
antimycobacteri
test
four
isol
demonstr
monoresist
suscept
pattern
two
rifmonoresist
one
inhmonoresist
one
ethmonoresist
one
isol
found
resist
two
drug
isoniazid
streptomycin
mycobacterium
tuberculosi
isol
centr
sensit
four
first
line
drug
test
although
five
isol
resist
either
one
two
antimycobacteri
none
resist
isoniazid
rifampicin
meant
mdrtb
present
particular
cohort
patient
still
effort
made
ensur
drugsuscept
patient
develop
mdrtb
futur
comparison
result
difficult
standardis
result
challeng
method
examin
perform
differ
loci
set
genotyp
mtb
isol
collect
period
larg
region
hospit
hong
kong
intermedi
tbburden
area
result
compar
lineag
classif
beij
nonbeij
genotyp
epidemiolog
correl
result
resolv
identifi
clearli
distribut
cluster
present
incorrect
relationship
beij
nonbeij
genotyp
mix
differ
lineag
cluster
misinterpret
nonbeij
cluster
within
beij
cluster
epidemiolog
linkag
within
cluster
confirm
similar
linkag
isol
howev
isol
show
incorrect
linkag
overal
display
accur
differenti
compar
conclus
result
show
excess
insuffici
number
loci
may
reduc
resolut
epidemiolog
link
cluster
experi
set
miruvntr
outperform
two
set
use
routin
genotyp
although
suffici
simpl
cluster
analysi
lineag
classif
epidemiolog
linkag
would
need
consid
multipl
method
increas
number
highli
variabl
loci
may
indic
order
achiev
optim
specif
clostridium
difficil
gramposit
spore
form
anaerob
human
pathogen
c
difficil
infect
cdi
worldwid
health
concern
diseas
symptom
rang
diarrhea
pseudomembran
coliti
case
toxic
megacolon
sepsi
death
cdi
usual
occur
result
intestin
dysbiosi
exposur
c
difficil
spore
current
treatment
strategi
reli
antibiot
usag
often
result
high
recurr
rate
might
increas
risk
develop
antibiot
resist
strain
previou
research
demonstr
mani
medium
chain
fatti
acid
mcfa
inhibit
growth
multipl
human
bacteri
pathogen
consequ
hypothes
mcfa
might
also
present
potenti
inhibitori
effect
c
difficil
show
lauric
acid
potent
antimicrobi
activ
multipl
toxigen
c
difficil
isol
present
low
cytotox
human
colon
epitheli
cell
mechan
inhibit
due
partli
gener
reactiv
oxygen
speci
ro
cell
membran
damag
biofilm
format
preform
biofilm
also
significantli
reduc
addit
lauric
acid
dosedepend
manner
murin
infect
model
lauric
acid
pretreat
lessen
cdi
symptom
reduc
proinflammatori
cytokin
product
taken
togeth
demonstr
natur
occur
mcfa
lauric
acid
novel
c
difficil
inhibitor
could
use
altern
treatment
cdi
fluoroquinolon
fq
potent
broadspectrum
antibiot
commonli
use
treat
sever
resist
bacteri
infect
howev
fq
resist
gramposit
neg
bacteria
emerg
easili
increas
global
mechan
fq
resist
known
multifactori
includ
one
mutat
target
gene
encod
dna
gyras
topoisomeras
iv
sinc
therapeut
choic
fqresist
bacteri
infect
becom
limit
would
necessari
develop
novel
antibiot
altern
minim
inhibit
fq
resist
bacteria
studi
examin
possibl
bactericid
effect
antisens
peptidepeptid
nucleic
acid
ppna
abl
block
express
dna
gyras
andor
topoisomeras
iv
fqresist
escherichia
coli
fre
result
demonstr
set
antisens
ppna
target
translat
initi
site
dna
gyras
topoisomeras
iv
gene
show
strongest
inhibitori
effect
growth
fre
isol
addit
bind
frespecif
code
sequenc
within
gyra
parc
gene
respect
possess
select
bactericid
effect
fre
isol
result
impli
potenti
antisens
ppna
antibiot
altern
fqresist
bacteria
resist
fluoroquinolon
main
subject
use
antibiot
substanc
veterinari
medicin
overus
misus
antibiot
major
caus
resist
optim
dose
dose
interv
essenti
achiev
clinic
cure
minim
emerg
fluoroquinolon
resist
purpos
studi
evalu
pharmacokineticpharmacodynam
pkpd
paramet
establish
reliabl
dose
enrofloxacin
chicken
salmonella
enteritidi
male
femal
broiler
chicken
week
old
assign
studi
enrofloxacin
dose
mgkg
bodi
weight
administ
per
oral
po
intraven
iv
rout
blood
sampl
collect
differ
time
interv
serum
concentr
drug
determin
minimum
inhibitori
concentr
mic
minimum
bactericid
concentr
mbc
enrofloxacin
differ
strain
enteritidi
determin
pharmacokinet
data
integr
pharmacodynam
data
determin
surrog
marker
antibacteri
activ
elimin
halflif
enrofloxacinwer
hr
iv
po
administr
respect
peak
concentr
c
max
time
c
max
reach
max
area
concentrationtim
curv
auc
hr
hr
ml
iv
hr
hr
ml
respect
bioavail
f
enrofloxacin
po
administr
mic
drug
differ
strain
enteritidi
found
pharmacodynam
data
integr
pharmacokinet
data
hr
area
concentrationtim
curv
auc
mic
c
max
mic
respect
iv
po
administr
conclud
enrofloxacin
dosag
mgkg
bodi
weight
iv
po
administr
hr
dose
interv
provid
effect
treatment
infect
chicken
enteritidi
data
indic
dosag
enrofloxacin
upsw
time
convent
recommend
dosag
introduct
respiratori
gastrointestin
diseas
import
caus
morbid
mortal
livestock
lead
econom
loss
continu
monitor
antimicrobi
suscept
veterinari
pathogen
need
abus
misus
antimicrobi
caus
emerg
antimicrobi
resist
studi
isol
cattl
pig
test
antimicrobi
suscept
materi
method
respiratori
gastrointestin
isol
collect
cattl
pig
nationwid
cattl
trueperella
pyogen
n
pasteurella
multocida
n
mannheimia
haemolytica
n
clostridium
difficil
n
c
perfringn
n
escherichia
coli
n
collect
isol
origin
pig
follow
pyogen
n
p
multocida
n
actinobacillu
pleuropneumonia
n
haemophilu
parasui
n
streptococcu
sui
n
salmonella
typhimurium
n
c
difficil
n
c
perfringen
n
e
coli
n
antimicrobi
suscept
test
perform
use
disc
diffus
method
result
overal
antimicrobi
resist
pattern
similar
cattl
pig
isol
isol
show
rel
high
resist
major
antimicrobi
e
coli
salmonella
exhibit
low
resist
ceftiofur
colistin
clostridium
sp
suscept
amoxicillin
florfenicol
doxycyclin
respiratori
pathogen
rel
low
resist
ceftiofur
cephalexin
amoxicillin
doxycyclin
conclus
studi
conduct
investig
antimicrobi
resist
bacteri
pathogen
south
korea
result
may
provid
recent
knowledg
establish
strategi
treatment
respiratori
gastrointestin
diseas
cattl
pig
abstract
use
lactic
acid
bacteria
probiot
food
increas
view
abil
posit
influenc
health
healthi
live
report
mine
bioinformat
strain
streptococcu
thermophilu
kld
rna
sequenc
also
carri
determin
closest
neighbor
strain
thermophilu
kld
genom
exopolysaccharid
product
mgl
closest
neighbour
includ
thermophilu
depth
amino
acid
code
gene
analysi
show
thermophilu
kld
synthes
twenti
essenti
amino
acid
requir
proper
bodi
function
well
anim
feed
formul
detail
import
understand
molecular
basi
behind
potenti
probiot
properti
also
give
new
insight
potenti
futur
applic
dairi
alli
industri
background
compon
diet
shown
strong
correl
spread
number
diseas
recent
year
especi
rapid
develop
omic
molecular
tool
larg
number
benefici
bacteri
strain
sequenc
thu
increas
understand
basi
current
potenti
health
benefit
second
import
lactic
acid
bacteria
world
sever
strain
streptococcu
thermophilu
shown
number
vitro
vivo
probiot
properti
recent
shown
thermophilu
kld
possess
total
epscod
gene
also
high
antimicrobi
activ
pathogen
aureu
e
coli
g
vaginali
report
data
bioinformat
strain
may
link
potenti
probiot
properti
methodolog
thermophilu
kld
strain
obtain
tradit
yoghurt
starter
cultur
inner
mongolia
china
whole
genom
sequenc
streptococcu
thermophilu
kld
perform
use
pacbio
rsii
k
librari
illumina
hiseq
pcrfree
librari
strategi
respect
hiseq
pacbio
clean
data
gener
use
refin
data
filter
pacbio
read
assembl
use
protocol
smrt
analysi
pipe
addit
phylogenet
tree
construct
show
evolutionari
statu
thermophilu
kld
base
rrna
analysi
ep
quantif
strain
determin
earlier
result
discuss
report
show
thermophilu
kld
display
similar
streptococcu
stain
deposit
ncbi
base
rrna
analysi
distinct
branch
kld
streptococcu
thermophilu
strain
phylogenet
tree
see
figur
thermophilu
atcc
found
closest
evolutionari
rel
kld
thu
result
strain
recogn
thermophilu
ssp
close
neighbour
includ
via
mgrast
analysi
includ
thermophilu
thermophilu
strain
studi
extens
previou
investig
genom
thermophilu
kld
consist
chromosom
g
c
content
see
figur
also
analyz
trna
statu
result
show
thermophilu
synthes
twenti
essenti
amino
acid
need
proper
bodi
function
adult
children
ep
product
stain
shown
approxim
mgl
ep
shown
probiot
properti
recent
report
studi
character
ep
well
optim
requir
explor
probiot
potenti
strain
amino
acid
profil
strain
confirm
capac
secret
twenti
essenti
amino
acid
necessari
proper
bodi
function
children
adult
amino
acidcod
gene
found
associ
product
leucin
lysin
methionin
alanin
valin
presenc
lysin
methionin
key
anim
feed
formul
strain
thu
potenti
food
industri
function
food
ingredi
starter
cultur
studi
condit
optim
amino
acid
product
recommend
presenc
cl
difficil
toxin
gene
tcda
tcdb
binari
toxin
also
detect
pcr
result
fecal
sampl
etec
isol
two
suckl
eleven
wean
pig
preval
ltstb
stastb
stb
thirteen
e
coli
isol
diarrheic
sampl
n
n
n
respect
one
e
coli
isol
nondiarrh
sampl
observ
lt
stb
toxin
cl
difficil
isol
n
diarrheic
sampl
observ
tcda
tcdb
binari
toxin
conclus
studi
reveal
ltstb
toxin
gene
commonli
present
etec
isol
wean
pig
diarrhea
c
difficil
isol
diarrheic
fecal
sampl
suckl
pig
observ
tcda
tcdb
binari
toxin
therefor
result
suggest
cl
difficil
etec
produc
tcda
tcdb
binari
toxin
ltstb
toxin
import
factor
diarrhea
piglet
korea
background
studi
aim
compar
pcr
method
serum
agglutin
test
sat
diagnosi
brucellosi
patient
six
month
treatment
method
peripher
blood
specimen
patient
brucellosi
case
group
subject
without
brucellosi
control
group
select
enter
studi
diagnosi
brucellosi
establish
use
sat
clinic
sign
symptom
compat
brucellosi
treatment
sat
pcr
done
case
month
complet
therapi
subject
control
group
assess
test
initi
visit
result
case
group
fifti
patient
male
femal
mean
age
year
evalu
mean
age
control
group
year
among
patient
whose
nest
pcr
assay
initi
posit
neg
six
month
treatment
relaps
occur
patient
within
six
month
treatment
pcr
posit
none
patient
control
group
pcr
posit
result
show
pcr
seem
highli
sensit
specif
therefor
use
method
initi
diagnosi
detect
relaps
chronic
brucellosi
background
plasmidborn
mobil
colistin
resist
gene
initi
identifi
china
subsequ
report
worldwid
recent
plasmid
identifi
escherichia
coli
isol
livestock
korea
investig
characterist
colistinresist
e
coli
plasmid
method
determin
growth
rate
competit
assay
perform
compar
bacteri
fit
plasmid
harbor
colistinresist
e
coli
nonplasmid
mediat
colistinresist
e
coli
strain
biofilmform
capac
assess
microtit
plate
method
nonplasmid
mediat
colistinresist
strain
mutat
express
level
basr
phopq
epta
gene
determin
lipid
structur
analyz
matrixassist
laser
desorptionion
timeofflight
malditof
mass
spectrometri
result
competit
e
coli
strain
reveal
differ
competit
fit
plasmid
mediat
nonplasmid
mediat
colistinresist
e
coli
strain
biofilm
assay
also
show
similar
level
biofilm
format
colistinsuscept
resist
strain
test
three
nonplasmid
mediat
colistinresist
strain
amino
acid
alter
bass
express
level
epta
significantli
increas
compar
colistinsuscept
strain
lipid
structur
plasmid
harbor
colistinresist
strain
modifi
addit
phosphoethanolamin
nonplasmid
mediat
colistinresist
strain
conclus
data
indic
plasmidborn
impair
fit
e
coli
lipid
modif
also
main
colistin
resist
mechan
along
epta
spread
transfer
colistinresist
determin
may
acceler
increas
colistin
resist
background
persist
cell
stay
dormant
form
antibiot
exist
make
difficult
remov
pathogen
complet
patient
result
treatment
failur
character
persist
format
acinetobact
baumannii
one
major
nosocomi
pathogen
materi
method
vitro
antimicrobi
suscept
test
perform
clinic
isol
baumannii
persist
assay
perform
four
antibiot
colistin
amikacin
imipenem
ciprofloxacin
character
properti
persist
format
froma
baumannii
persist
assay
perform
variou
way
serial
persist
assay
also
perform
two
random
persist
coloni
surviv
first
persist
assay
reinocul
fresh
lb
broth
incub
overnight
second
persist
assay
perform
overnight
cultur
protocol
result
four
antibiot
correl
persist
rate
specif
strain
isol
exhibit
high
persist
cell
format
rate
one
antibiot
necessarili
show
high
rate
persist
product
antibiot
persist
format
rate
antibiot
almost
constant
persist
assay
repeat
three
time
serial
persist
assay
regrown
persist
cell
antibioticfre
media
show
persist
format
rate
initi
one
conclus
data
suggest
persist
cell
form
differ
mechan
antibiot
persist
rate
antibiot
intrins
properti
strain
carbapenem
use
treatment
bacteri
infect
reliabl
lastlin
drug
howev
abus
carbapenem
carbapenemaseproduc
enterobacteriacea
cpe
well
carbapenemresist
enterobacteriacea
cre
emerg
worldwid
korea
laboratori
submit
suspect
cre
isol
kcdc
confirm
cre
carbapenemaseproduct
studi
confirm
analyz
characterist
cre
isol
like
speci
identif
carbapenem
resist
pattern
carbapenemas
gene
type
antimicrobi
suscept
examin
broth
microdilut
disk
diffus
method
use
clsi
guidelin
carbapenemas
gene
imp
vim
ndm
kpc
ge
investig
pcr
analyz
sequenc
align
method
total
cre
suspect
isol
collect
januari
june
isol
enterobacteriacea
nonenterobacteriacea
ratio
cre
cie
cse
respect
among
cre
isol
isol
klebsiella
pneumonia
escherichia
coli
enterobact
spp
preval
type
cre
isol
occurr
addit
isol
show
cpe
posit
harbor
bla
bla
gene
respect
cpe
one
carbapenemas
gene
isol
harbor
gene
time
predomin
type
bla
bla
type
isol
conclus
june
mandatori
submiss
system
suspect
cre
start
korea
continu
monitor
cre
occurr
characterist
chang
investig
report
background
fluoroquinolon
one
commonli
use
antibiot
treatment
infect
caus
streptococcu
pneumonia
howev
rate
fluoroquinolon
resist
increas
accord
frequent
use
design
studi
verifi
current
fluoroquinolon
resist
rate
risk
factor
communityonset
pneumococc
pneumonia
method
retrospect
casecontrol
studi
conduct
tertiari
referr
hospit
studi
popul
compos
patient
admit
pneumococc
pneumonia
januari
may
case
group
includ
communityonset
pneumonia
caus
levofloxacinnonsuscept
pneumonia
control
group
consist
patient
admit
around
time
case
among
patient
levofloxacinsuscept
pneumonia
result
total
pneumococc
pneumonia
identifi
studi
period
levofloxacinresist
pneumonia
levofloxacinintermedi
pneumonia
includ
case
group
nonsuscept
rate
levofloxacin
multivari
analysi
show
recent
hospit
ci
p
underli
bronchopulmonari
diseas
ci
p
cerebrovascular
diseas
ci
p
prior
antibiot
use
within
month
ci
p
associ
levofloxacin
nonsuscept
conclus
independ
risk
factor
levofloxacin
nonsuscept
pneumococc
pneumonia
recent
hospit
bronchopulmonari
diseas
cerebrovascular
diseas
prior
antibiot
use
within
month
care
choic
empir
antibiot
need
among
group
correl
fraction
inhibitori
concentr
index
mutant
select
index
antimicrobi
combin
x
xu
l
xu
g
yuan
j
li
colleg
bioscienc
bioengin
jiangxi
agricultur
univers
nanchang
china
abstract
antimicrobi
resist
serious
threaten
human
health
combin
therapi
gener
consid
effect
strategi
prevent
resist
gener
benefit
difficult
conclus
demonstr
valid
synergist
combin
mention
probabl
key
accord
hypothes
mutant
prevent
concentr
mpc
mutant
select
window
msw
combin
mutant
select
index
si
ratio
mpc
combin
mic
alon
agent
less
equal
one
would
efficaci
prevent
antimicrobi
resist
correl
si
fraction
inhibitori
concentr
index
fici
use
evalu
synergi
effect
antimicrobi
agent
use
checkerboard
assay
agar
plate
linear
concentr
decreas
research
mutant
si
five
antimicrobi
agent
alon
fici
si
three
combin
includ
twentyon
differ
proport
methicillinresist
staphylococcu
aureu
mrsa
figur
indic
smaller
fici
two
agent
combin
probabl
si
less
equal
one
wider
proport
rang
two
agent
close
msw
minimum
fici
less
equal
combin
two
agent
close
msw
could
sought
differ
proport
differ
proport
two
agent
combin
present
differ
si
one
synergist
valid
vivo
would
accordingli
dicount
due
differ
pharmacokinet
synergist
antimicrobi
agent
simliar
pharmacokinet
combin
must
favor
prevent
resist
maximum
fici
perfectli
less
period
remark
increas
mainli
due
increas
serotyp
korea
addit
consist
serotyp
also
found
frequent
found
conclus
studi
show
persist
high
preval
macrolid
resist
increas
number
pneumococci
carri
erm
b
mef
korea
given
current
epidemiolog
macrolid
resist
empir
use
macrolid
alon
may
appropri
choic
treatment
pneumococc
infect
adult
patient
korea
therefor
continu
surveil
pneumococc
epidemiolog
macrolid
resist
would
necessari
accord
clinic
laboratori
standard
institut
clsi
guidelin
agar
broth
dilut
method
use
detect
vancomycin
resist
staphylococcu
aureu
howev
recent
advanc
autom
devic
led
increas
use
autom
instrument
hospit
studi
compar
result
vancomycin
suscept
test
agar
broth
dilut
method
instrument
use
vancomycin
mic
ugml
staphylococcu
aureu
strain
etest
method
total
strain
use
experi
collect
year
vancomycin
resist
staphylococcu
aureu
surveil
system
korea
accord
agar
dilut
broth
dilut
strain
differ
strain
resist
suscept
affect
accord
agar
broth
dilut
method
instrument
respect
result
instrument
show
time
higher
mic
strain
time
higher
mic
result
strain
clsi
method
result
chang
vancomycin
suscept
mic
intermedi
mic
mic
suscept
detail
accord
analysi
accomplish
vancomycin
suscept
use
larg
number
strain
variou
vancomycin
mic
suscept
studi
show
result
need
addit
broth
dilut
experi
vancomycin
resist
suscept
confirm
btb
preval
anim
herd
level
beef
cattl
dairi
cattl
respect
overal
preval
anim
herd
level
respect
five
risk
factor
offer
invari
logist
regress
model
farm
higher
number
cattl
one
posit
anim
time
risk
establish
btb
respect
compar
farm
one
btb
outbreak
conclus
understand
first
report
encompass
dairi
beef
farm
south
korea
furthermor
result
risk
factor
analysi
use
entri
point
futur
inform
decis
make
toward
btb
control
erad
program
countri
conclus
data
show
ltbi
preval
among
hcw
work
hospit
increas
tendenc
age
physician
less
like
accept
treatment
hcw
find
suggest
effort
enhanc
ltbi
treatment
accept
among
physician
need
background
bovin
tuberculosi
btb
remain
import
diseas
mani
countri
world
caus
signific
econom
loss
prove
difficult
control
detect
method
residu
mycobacterium
bovi
bovi
environ
need
control
btb
herd
level
nest
pcr
amplif
appli
studi
ensur
specif
detect
elimin
falseposit
result
increas
amplif
signal
provid
method
highest
sensit
environment
sampl
studi
attempt
establish
method
detect
bovi
environment
sampl
use
nestedpcr
method
detect
residu
bovi
cattl
herd
carri
disinfect
materi
method
environment
sampl
fecal
sampl
bottl
water
herd
herd
histori
btb
outbreak
use
detect
residu
mycobacterium
bovi
amplicon
librari
target
gene
fragment
amplifi
bovi
dna
use
two
type
primer
set
first
step
pcr
amplif
bp
length
gene
perform
sampl
purifi
remov
other
purifi
librari
amplicon
reamplifi
second
pcr
primer
set
bp
increas
detect
sensit
pcr
amplif
round
size
pcr
product
verifi
agaros
gel
result
result
detect
residu
bovi
environment
sampl
fecal
sampl
dna
shown
posit
band
nest
pcr
method
sampl
water
sampl
detect
posit
result
detect
bovi
use
nest
pcr
method
found
higher
commonli
use
pcr
method
sensit
specif
two
method
base
polymeras
chain
reaction
pcr
detect
bovi
compar
standard
pcr
method
sensit
detect
bovi
low
due
contamin
microorgan
environment
sampl
howev
sensit
nestedpcr
bovi
high
compar
previou
one
use
detect
method
environment
sampl
due
resist
outsid
environ
btb
often
report
recurr
outbreak
herd
therefor
import
carri
thorough
hygien
manag
test
slaughter
reactor
nestedpcr
use
use
tool
screen
mycobacterium
bovi
environment
sampl
one
method
control
btb
herd
level
case
common
site
tb
present
cn
involv
third
common
present
case
follow
tb
lymphadenopathi
case
pleurisi
case
pericardi
involv
case
skin
involv
patient
other
case
patient
posit
quantiferontb
gold
assay
result
indetermin
result
percentag
posit
quantiferontb
gold
assay
result
highest
proven
tb
group
follow
probabl
tb
group
possibl
tb
group
p
proven
case
case
neg
quantiferontb
incub
hour
antimouseantibodi
sigma
ad
lastli
tmb
bd
bioscienc
ad
well
stop
solut
ad
well
final
optic
densiti
measur
nm
elisa
purpos
elisa
observ
bind
mrid
fuse
rbd
merscov
infect
rabbit
human
serum
mersinfect
cell
lysat
merscovkorknih
mrid
fuse
rbd
load
onto
nunc
immunopl
thermo
fisher
scientif
coat
end
procedur
wash
ul
pbst
three
time
block
buffer
bsa
pbst
treat
allow
two
hour
reaction
time
rt
merscov
infect
rabbit
sera
start
ug
ug
patient
serum
dilut
place
well
ulwel
two
hour
incub
rt
dilut
antibodi
goat
antihuman
igg
antibodi
kpl
ad
measur
ul
per
well
anoth
hour
incub
rt
tmb
bd
bioscienc
ad
ad
reaction
stop
ad
stop
solut
h
well
final
optic
densiti
measur
target
protein
design
clone
express
target
protein
use
rid
fusion
partner
express
merscov
antigen
e
coli
amino
acid
rid
amongst
lysr
use
fusion
partner
fig
depend
speci
immun
hrid
mrid
use
clone
minim
induc
immun
fusion
partner
follow
scheme
simpl
illustr
rnamedi
fold
model
produc
fold
target
protein
cleav
fusion
partner
use
tev
proteas
fig
select
base
antigen
plot
predict
previou
studi
rbd
play
key
role
bind
receptor
select
target
protein
fig
mrid
mousederiv
rid
use
fusion
partner
express
solubl
improv
temperatur
decreas
compar
solubl
direct
form
fig
fold
ridfus
protein
role
rna
stabil
mainten
accord
former
studi
mani
peopl
believ
protein
fold
carri
molecular
chaperon
howev
recent
research
show
rna
function
chaperon
aid
protein
fold
stabil
thu
carri
cell
lysi
verifi
role
rna
ridfus
protein
fold
stabil
mainten
rna
remov
invitro
anoth
incub
control
agaros
gel
verifi
rna
remov
treat
rnase
fig
addit
sdspage
analysi
use
western
blot
coomassi
stain
confirm
mrid
fuse
protein
show
decreas
solubl
rna
remov
fig
rid
fuse
rbd
protein
bound
receptor
verifi
bind
rbd
protein
produc
e
coli
system
receptor
use
coimmunoprecipit
elisa
first
bind
rbd
protein
verifi
use
coimmunoprecipit
protein
magnet
bead
antibodi
perform
western
blot
fig
also
use
protein
coat
antigen
observ
bind
rbd
protein
concentrationdepend
antihi
antibodi
use
elisa
assay
verif
fig
find
conclud
success
fold
e
coli
deriv
rbd
protein
result
bind
receptor
serodiagnosi
base
rbd
antigen
merscov
infect
serum
predict
mrid
fuse
rbd
protein
suitabl
serodiagnosi
thu
rbd
use
coat
antigen
rabbit
sera
immun
inactiv
merscov
serial
dilut
first
elisa
assay
identifi
bind
rbd
merscov
immun
rabbit
sera
fig
furthermor
elisa
perform
use
sera
dilut
four
patient
infect
merscov
rbd
coat
antigen
bind
sensit
three
merscov
infect
patient
sera
higher
merscov
infect
cell
lysat
fig
howev
dilut
normal
person
sera
almost
none
detect
ridfus
rbd
result
demonstr
mridfus
rbd
serv
power
antigen
rapid
accur
diagnosi
mass
product
preced
research
paper
merscov
introduc
method
produc
spike
protein
insect
cell
use
target
epitop
howev
drawback
preexist
method
includ
high
cost
low
product
output
therefor
certainli
necessari
massproduc
appropri
diagnost
antigen
low
cost
time
effici
manner
conclus
first
time
employ
chaperna
rnamedi
chaperon
produc
potenti
serodiagnost
antigen
rbd
e
coli
diagnos
patient
anim
infect
merscov
use
elisa
verifi
antigen
bind
patient
serum
higher
affin
merscov
infect
cell
lysat
also
abl
establish
high
accur
diagnost
techniqu
use
addit
antigen
doublecheck
verifi
diagnosi
platform
becom
extens
applic
merscov
also
outbreak
variou
pandem
virus
allow
quick
diagnosi
continu
endeavor
improv
appli
rnadepend
fold
system
diagnost
prophylact
applic
ongo
research
dedic
har
chaperna
assembl
vaccin
antigen
nanoparticl
gain
high
neutral
capac
sever
fever
thrombocytopenia
syndrom
associ
hemophagocyt
lymphohistiocytosi
review
case
bone
marrow
studi
park
j
studi
electrocardiograph
ecg
chang
myocardi
dysfunct
method
studi
patient
diagnos
sft
five
hospit
daegu
korea
januari
novemb
review
medic
record
retrospect
result
abnorm
ecg
chang
observ
patient
hospit
among
patient
arrhythm
chang
ischem
chang
atrial
fibrilli
atrial
flutter
paroxysm
supraventricular
tachycardia
wave
invers
normal
sinu
rhythm
also
chang
hospit
patient
taken
next
ecg
patient
abnorm
ecg
older
normal
ecg
group
also
pulmonari
edema
frequent
ecg
abnorm
occur
frequent
death
group
vs
p
conclus
studi
show
high
proport
sft
patient
ecg
chang
cardiac
involv
sftsv
clear
lot
patient
abnorm
ecg
frequent
involv
fatal
case
addit
studi
need
cardiac
involv
sftsv
sinc
outbreak
hendra
viru
nipah
viru
asia
sever
henipavirus
detect
assay
base
realtim
revers
transcript
polymeras
chain
reaction
rrtpcr
develop
studi
analyt
valid
assay
perform
evalu
sensit
reliabl
prepared
henipaviru
outbreak
assay
target
hendra
viru
matrix
gene
nipah
viru
nucleoprotein
n
gene
evalu
sensit
calcul
limit
detect
lod
estim
among
replic
copiesreact
assay
target
hendra
viru
nipah
viru
phosphaprotein
gene
p
also
evalu
perform
assay
system
compar
test
vitro
transcrib
rna
sampl
result
demonstr
assay
reliabl
tool
rapid
diagnosi
clinic
surveil
epidemiolog
studi
suspect
henipaviru
case
formerli
sampl
test
influenza
virus
rtpcr
full
length
hemagglutinin
gene
isol
sequenc
use
sanger
method
also
sampl
includ
previou
isol
full
genom
segment
obtain
miseq
platform
illumina
phylogenet
tree
gener
use
mega
correl
plot
construct
amino
acid
substitut
phylogenet
tree
analysi
reveal
isol
ainfluenza
virus
belong
subclad
correl
plot
use
amino
acid
substitut
ha
isol
reveal
substitut
posit
neg
correl
substitut
respect
suggest
obviou
characterist
virus
new
subgroup
also
full
genom
segment
miseq
platform
reveal
variou
correl
result
isol
virus
period
season
sampl
substitut
mutat
one
key
characterist
clade
repres
viru
vaccin
strain
previou
season
